Anti-il-13 antibodies and methods of use thereof

Abstract

The disclosure provides, in various embodiments, antibodies, antigen-binding fragments thereof, and compositions (e.g., pharmaceutical composition) comprising said antibodies, or antigen-binding fragments thereof, that bind to interleukin-13 (IL-13) and methods for using the same in the treatment of a subject having an IL-13-associated disease or condition.

Description

Attorney Docket No: 134524-5009- WOANTI-IL-13 ANTIBODIES AND METHODS OF USE THEREOFFIELD

[0001] Provided herein are antibodies and antigen binding fragments thereof that bind to interleukin-13 (IL-13).CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] The present application claims the benefit of and priority to U. S. Patent Application No.63 / 755,420 filed on February 7, 2025; U. S. Patent Application No. 63 / 769,909 filed on March 11, 2025; U. S. Patent Application No. 63 / 961,677 filed on January 16, 2026; and U. S. Patent Application No. 63 / 972,447, filed on January 30, 2026, entitled “ANTI-IL-13 ANTIBODIES AND METHODS OF USE THEREOF,” each of which is incorporated herein by reference in its entirety.SEQUENCE LISTING

[0003] This application contains a sequence listing, which has been submitted in XML format via Patent Center. The contents of the XML copy named “134524-5009-WO_Sequence_Listing.xml” which was created on January 30, 2026, and is 292,646 bytes in size, are incorporated herein by reference in their entirety.BACKGROUND

[0004] IL-13 (also known as Interleukin-13 or NC30) is a cytokine protein which is produced by immune cells such as T helper type 2 (Th2) cells (see, e.g., Rael and Lockey, World Allergy Organ J. 4:54-64; 2011). It is largely found in the extracellular matrix and regulates physiological cellular changes related to allergic inflammation across many tissues (see, e.g., Minty et. al., Nature. 362:248-250; 1993).

[0005] IL-13 plays many immunological roles in the cell. For example, it stimulates B cell proliferation and is involved in the activation of other immune cells including eosinophils, basophils, and mast cells (see, e.g., Defrance et. al., J Exp Med. 179:135-143; 1994; Luttmann et. al., J Immunol. 157:1678-1683; 1996). Importantly, IL-13 contributes to IgE synthesis fromAttorney Docket No: 134524-5009- WOactivated B cells, wherein high levels of IgE antibodies are characteristic of parasitic infection or an allergic response (see, e.g., Punnonen et. al., J Allergy Clin Immunol. 100(6):792-801; 1997).

[0006] IL-13 is considered to be a key driver of inflammation in autoimmune diseases such as atopic dermatitis where it is found to be overexpressed in skin lesions. Despite development of treatments for IL-13 mediated diseases and disorders such treatments are inefficacious due to requirement for repeated dosing every 2-4 weeks resulting in lack of patient compliance to the course of maintenance therapy. Accordingly, a need exists for additional therapeutics that offer extended dosing frequency as a means to improve patient compliance and response to course of treatment.SUMMARY

[0007] There is a critical need for therapeutic agents for modulating (e.g., reducing or neutralizing) IL-13 binding and / or activity. The present disclosure provides methods of modulating IL-13 binding and / or activity and methods of treating IL-13 -associated diseases or conditions using an antibody or antigen-binding fragment thereof as described herein.

[0008] The present disclosure provides for methods of using anti-IL-13 antibodies, or antigenbinding fragments thereof, or compositions comprising anti-IL-13 antibodies, or antigen-binding fragments thereof, for use in the treatment of diseases in a subject.

[0009] In one aspect, the present disclosure provides a method of treating an IL-13-mediated disease in a subject, comprising administering to the subject a therapeutically effective dose of about 10 mg to about 1500 mg of an antibody, or antigen-binding fragment thereof, at an interval of about every 3 months to about every 12 months, wherein the antibody, or antigen-binding fragment thereof, comprises: a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 6, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 3; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 10, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 7, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a LCDR3 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No: 134524-5009- WO9; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 16, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 17, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 18, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 15; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 22, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 23, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 24, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 19, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 21; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 28, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 29, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 30, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 25, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 27; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 36, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 31, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 32, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 33; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 40, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 41, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 42, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 37, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 39; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 46, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 47, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 43, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 45; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 52, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 53,Attorney Docket No: 134524-5009- WOand a HCDR3 comprising the amino acid sequence of SEQ ID NO: 54, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 49, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 50, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 51; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 58, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 60, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 55, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 57; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 66, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 61, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 63; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 70, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 72, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 67, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 69; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 76, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 78, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 75; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 82, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 84, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 81; a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 88, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 90, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO:Attorney Docket No: 134524-5009- WO85, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 87; ora heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 94, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 96, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 91, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 93.

[0010] In some embodiments, the therapeutically effective dose is about 10 mg to about 1500 mg, about 200 mg to about 1400 mg, about 250 mg to about 1300 mg, or about 300 mg to about 1200 mg (e.g., 300 mg, 600 mg, or 1200 mg).

[0011] In some embodiments, the therapeutically effective dose is administered about every 3 months, about every 4 months, about every 6 months, about every 9 months, or about every 12 months. In some embodiments, the therapeutically effective dose is administered about every 6 months. In some embodiments, the therapeutically effective dose is administered about every 24 weeks, about every 26 weeks, or about every 28 weeks.

[0012] In some embodiments, the therapeutically effective dose is administered subcutaneously, intravenously, intramuscularly, or intraperitoneally.

[0013] In some embodiments, the therapeutically effective dose is administered subcutaneously as a single dose of about 10 mg, about 30 mg, about 100 mg, about 300 mg, about 600 mg, about 1200 mg, or about 1500 mg.

[0014] In some embodiments, the therapeutically effective dose is administered subcutaneously as two doses of about 100 mg, two doses of about 300 mg, two doses of about 600 mg, or two doses of about 1200 mg. In some embodiments, the two 100 mg doses, the two 300 mg doses, the two 600 mg doses, or the two 1200 mg doses are administered on about day 1 and about day 15.

[0015] In some embodiments, the IL-13-mediated disease is a chronic and / or an allergic inflammatory skin disease. In some embodiments, the IL-13-mediated disease is selected from the group consisting of: asthma (including, but not limited to, mild asthma, mild to moderate asthma, moderate asthma, moderate to severe asthma, and / or severe asthma), allergic asthma, allergen-induced airway obstruction due to asthma and / or allergic asthma, atopic dermatitis (including, but not limited to, mild atopic dermatitis, mild to moderate atopic dermatitis, moderate atopic dermatitis, moderate-to-severe, and / or severe atopic dermatitis), eczema, acute urticaria,Attorney Docket No: 134524-5009- WOidiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), chronic obstructive airway disease, emphysema, chronic bronchitis, pulmonary fibrosis, systemic sclerosis, scleroderma, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, idiopathic interstitial pneumonitis, wound, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), ulcerative colitis (UC), type 1 diabetes (T1D), sjogren's syndrome (SS), prurigo nodularis, nasal polyposis, recurrent urticaria, aspergillosis, bullous pemphigoid, chronic sinusitis, alopecia areata, hay fever, pemphigus, allergic rhinitis, psoriasis, rosacea, allergic drug reactions, allergic reactions, anaphylaxis, acne, food allergies, inflammatory bowel disease (IBS), Crohn’s disease, ulcerative colitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, eosinophilic colitis, eosinophilic gastritis, eosinophilic cystitis, eosinophilic fasciitis, eosinophilic pustular folliculitis, eosinophilic granulomatosis, eosinophilic polyangiitis, Churg-Strauss syndrome, biliary cancer, brain cancer, breast cancer, colorectal cancer, genitourinary cancer, head and neck cancer, liver cancer, Hodgkin's lymphoma, esophageal cancer, pancreatic cancer, prostate cancer, renal cancer, Kaposi's sarcoma, sinusitis, or chronic urticaria. In some embodiments, the IL-13-mediated disease increases itching, eczema, dry and scaly skin, red and inflamed patches, thickened skin, blistering, crusting, scaling, skin sensitivity, or a combination thereof.

[0016] In some embodiments, a method of the present disclosure provides administering an antibody disclosed herein, or antigen-binding fragment thereof, to a human subject. In some embodiments, the human subject is adult. In some embodiments, the human subject is a child.

[0017] In some embodiments, administering an effective dose of an antibody disclosed herein, or antigen-binding fragment thereof, decreases the level of eosinophils in a blood, and / or urine sample from the subject as compared to a blood, and / or urine sample collected from the subject prior to administering.

[0018] In some embodiments, administering an effective dose of an antibody disclosed herein, or antigen-binding fragment thereof, decreases the level of leukocytes in a blood, and / or urine sample from the subject as compared to a blood, and / or urine sample collected from the subject prior to administering.

[0019] In some embodiments, administering the therapeutically effective dose of an antibody disclosed herein, or antigen-binding fragment thereof, achieves a serum half-life of the antibody, or antigen-binding fragment thereof, in a subject of about 50 to about 150 days (e.g., about 100 days).Attorney Docket No: 134524-5009- WO

[0020] In some embodiments, administering the therapeutically effective dose of an antibody disclosed herein, or antigen-binding fragment thereof, achieves a maximum serum concentration (Cmax) of the antibody, or antigen-binding fragment thereof, in a subject of about 3 μg / ml to about 300 μg / ml.

[0021] In some embodiments, administering the therapeutically effective dose of an antibody disclosed herein, or antigen-binding fragment thereof, achieves a serum AUC0-7dvalue of the antibody, or antigen-binding fragment thereof, in the subject of about 3 μg·day / ml to about 300 μg·day / ml.

[0022] In some embodiments, a method of the present disclosure comprises administering an antibody, or antigen-binding fragment thereof comprising: a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 98, and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 97; a VH comprising an amino acid sequence of SEQ ID NO: 100, and a VL comprising an amino acid sequence of SEQ ID NO: 99; a VH comprising an amino acid sequence of SEQ ID NO: 102, and a VL comprising an amino acid sequence of SEQ ID NO: 101; a VH comprising an amino acid sequence of SEQ ID NO: 104, and a VL comprising an amino acid sequence of SEQ ID NO: 103; a VH comprising an amino acid sequence of SEQ ID NO: 106, and a VL comprising an amino acid sequence of SEQ ID NO: 105; a VH comprising an amino acid sequence of SEQ ID NO: 108, and a VL comprising an amino acid sequence of SEQ ID NO: 107; a VH comprising an amino acid sequence of SEQ ID NO: 110, and a VL comprising an amino acid sequence of SEQ ID NO: 109; a VH comprising an amino acid sequence of SEQ ID NO: 112, and a VL comprising an amino acid sequence of SEQ ID NO: 111; a VH comprising an amino acid sequence of SEQ ID NO: 114, and a VL comprising an amino acid sequence of SEQ ID NO: 113; a VH comprising an amino acid sequence of SEQ ID NO: 116, and a VL comprising an amino acid sequence of SEQ ID NO: 115; a VH comprising an amino acid sequence of SEQ ID NO: 118, and a VL comprising an amino acid sequence of SEQ ID NO: 117; a VH comprising an amino acid sequence of SEQ ID NO: 120, and a VL comprising an amino acid sequence of SEQ ID NO: 119; a VH comprising an amino acid sequence of SEQ ID NO: 122, and a VL comprising an amino acid sequence of SEQ ID NO: 121; a VH comprising an amino acid sequence of SEQ ID NO: 124, and a VL comprising an amino acid sequence of SEQ ID NO: 123; a VH comprising an amino acid sequence of SEQ ID NO: 126, and a VL comprising an amino acid sequence of SEQ ID NO: 125; or a VH comprising an amino acid sequence of SEQ ID NO: 128, and a VL comprising an amino acid sequence of SEQ ID NO: 127.Attorney Docket No: 134524-5009- WO

[0023] In some embodiments, the disclosed antibody, or antigen-binding fragment thereof is a human IgG1 isotype antibody.

[0024] In some embodiments, a method of the present disclosure comprises administering an antibody, or antigen-binding fragment thereof comprising: a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 130, and a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 129; a HC comprising an amino acid sequence of SEQ ID NO: 132, and a LC comprising an amino acid sequence of SEQ ID NO: 131; a HC comprising an amino acid sequence of SEQ ID NO: 134, and a LC comprising an amino acid sequence of SEQ ID NO: 133; a HC comprising an amino acid sequence of SEQ ID NO: 136, and a LC comprising an amino acid sequence of SEQ ID NO: 135; a HC comprising an amino acid sequence of SEQ ID NO: 138, and a LC comprising an amino acid sequence of SEQ ID NO: 137; a HC comprising an amino acid sequence of SEQ ID NO: 140, and a LC comprising an amino acid sequence of SEQ ID NO: 139; a HC comprising an amino acid sequence of SEQ ID NO: 142, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 144, and a LC comprising an amino acid sequence of SEQ ID NO: 143; a HC comprising an amino acid sequence of SEQ ID NO: 146, and a LC comprising an amino acid sequence of SEQ ID NO: 145; a HC comprising an amino acid sequence of SEQ ID NO: 148, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 150, and a LC comprising an amino acid sequence of SEQ ID NO: 149; a HC comprising an amino acid sequence of SEQ ID NO: 152, and a LC comprising an amino acid sequence of SEQ ID NO: 151; a HC comprising an amino acid sequence of SEQ ID NO: 154, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 156, and a LC comprising an amino acid sequence of SEQ ID NO: 155; a HC comprising an amino acid sequence of SEQ ID NO: 158, and a LC comprising an amino acid sequence of SEQ ID NO: 157; a HC comprising an amino acid sequence of SEQ ID NO: 160, and a LC comprising an amino acid sequence of SEQ ID NO: 159; a HC comprising an amino acid sequence of SEQ ID NO: 182, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 183, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 184, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 185, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 186, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 187, and a LC comprising an amino acid sequence of SEQAttorney Docket No: 134524-5009- WOID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 188, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 189, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 190, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 191, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 192, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 193, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 194, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 195, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 196, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 197, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 198, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 199, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 200, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 201, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 202, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 203, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 204, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 205, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 206, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 207, and a LC comprising an amino acid sequence of SEQ ID NO: 147; a HC comprising an amino acid sequence of SEQ ID NO: 208, and a LC comprising an amino acid sequence of SEQ ID NO: 141; a HC comprising an amino acid sequence of SEQ ID NO: 209, and a LC comprising an amino acid sequence of SEQ ID NO: 153; a HC comprising an amino acid sequence of SEQ ID NO: 210, and a LC comprising an amino acid sequence of SEQ ID NO: 147; or a HC comprising an amino acid sequence of SEQ ID NO: 211, and a LC comprising an amino acid sequence of SEQ ID NO: 141.Attorney Docket No: 134524-5009- WO

[0025] In one aspect, the present disclosure provides a method of treating an IL-13-mediated disease in a human patient, comprising administering to the patient a therapeutically effective dose of about 10 mg to about 1200 mg of an antibody at an interval of about every 24 weeks to about every 28 weeks, wherein the antibody comprises the presently disclosed heavy chain (HC) and a light chain (LC) amino acid sequences.

[0026] In some embodiments, a method of the present disclosure comprises administering to the human patient: about 10 mg of the antibody at an interval of about every 24 weeks; about 10 mg of the antibody at an interval of about every 26 weeks; about 10 mg of the antibody at an interval of about every 6 months; about 10 mg of the antibody at an interval of about every 28 weeks; about 30 mg of the antibody at an interval of about every 24 weeks; about 30 mg of the antibody at an interval of about every 26 weeks; about 30 mg of the antibody at an interval of about every 6 months; about 30 mg of the antibody at an interval of about every 28 weeks; about 100 mg of the antibody at an interval of about every 24 weeks; about 100 mg of the antibody at an interval of about every 26 weeks; about 100 mg of the antibody at an interval of about every 6 months; about 100 mg of the antibody at an interval of about every 28 weeks; about 300 mg of the antibody at an interval of about every 24 weeks; about 300 mg of the antibody at an interval of about every 26 weeks; about 300 mg of the antibody at an interval of about every 6 months; about 300 mg of the antibody at an interval of about every 28 weeks; about 600 mg of the antibody at an interval of about every 24 weeks; about 600 mg of the antibody at an interval of about every 26 weeks; about 600 mg of the antibody at an interval of about every 6 months; about 600 mg of the antibody at an interval of about every 28 weeks; about 1200 mg of the antibody at an interval of about every 24 weeks; about 1200 mg of the antibody at an interval of about every 26 weeks; about 1200 mg of the antibody at an interval of about every 6 months; or about 1200 mg of the antibody at an interval of about every 28 weeks.

[0027] In some embodiments, a method of the present disclosure comprises administering a therapeutically effective dose of the disclosed antibody subcutaneously.

[0028] In some embodiments, the therapeutically effective dose is administered subcutaneously as a single dose or as two separate doses. In some embodiments, the disclosed two separate doses comprise a first dose administered at about day 1 and second dose administered at about day 15. In some embodiments, the first dose and the second dose comprise the same amount of the antibody.Attorney Docket No: 134524-5009- WOBRIEF DESCRIPTION OF THE DRAWINGS

[0029] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0030] The foregoing will be apparent from the following more particular description of example embodiments, as illustrated in the accompanying drawings in which like reference characters refer to the same parts throughout the different views. The drawings are not necessarily to scale, emphasis instead being placed upon illustrating embodiments.

[0031] FIG. 1A to FIG. 1F demonstrate anti-IL-13 antibodies neutralizing the IL- 13 expressed on HEK-Blue cells. HEK-Blue cells expressing IL-13Ra1 / IL-4Ra, STAT6 and a STAT6-inducible SEAP reporter was induced using IL-13 in the presence of the indicated molecules and percent inhibition of SEAP reporter was measured. Ref1 is reference molecule and a positive control. Data are analyzed by normalizing response to the IgG1 isotype negative control to obtain percent inhibition. Percent inhibition induced by AbA and AbB (FIG. 1A), AbC, AbE and AbF (FIG. 1 B), AbG, AbH and Abl (FIG. 1C), AbD, AbJ and AbK (FIG. 1D), AbL, AbM and AbN (FIG. 1E), and AbO and AbP (FIG. 1F) are shown. IC50values are calculated by fitting a 4-parameter non-linear regression curve using the average of four technical replicates per antibody concentration.

[0032] FIG. 2 demonstrates an anti-IL-13 antibody (Antibody AbAB) blocking IL-13 and inhibiting pSTAT6 induced SEAP reporter activity in the HEK-Blue IL-4 / IL-13 Assay. Results displayed are expressed in percent inhibition (n=3 technical replicates from one representative biological replicate) as a function of the antibody concentration, as compared to stimulated but unblocked cells (IL- 13 alone), as mean + / - SEM.

[0033] FIG. 3 demonstrates an anti-IL-13 antibody blocking human IL-13 and downstream pSTAT6 signaling in human monocytes (n=3 technical replicates from Donor 3). Results displayed are expressed in percent inhibition of pSTAT6 signal as a function of the antibody concentration, as compared to an isotype control, as mean + / - SEM.

[0034] FIG. 4 demonstrates an anti-IL-13 antibody blocking cynomolgus IL-13 and downstream pSTAT6 signal on cynomolgus monocytes (n=3 technical replicates from Donor 1). Results displayed are expressed in percent inhibition of pSTAT6 signal as a function of the antibody concentration, as compared to an isotype control, as mean + / - SEM.Attorney Docket No: 134524-5009- WO

[0035] FIG. 5 is a schematic illustrating an exemplary hlL-13 administration and anti-IL-13 antibody dosing schedule in C57BL / 6 mice. Animals in the vehicle control group received PBS intranasally every two days (Days 0-10). All other groups were administered 20 µL of 0.25 mg / mL IL-13 (5 µg / mouse) intranasally over the same period. Antibodies were administered via intraperitoneal (i.p.) injection on Days -1 and 5. On Day 11, serum and bronchoalveolar lavage fluid (BALF) samples were collected for measurement of total IgE and eotaxin / CCL11 levels using ELISA. Cell counts and flow cytometry were performed on BALF samples. Lung tissues were assessed for mucus overproduction and goblet cell metaplasia using Periodic acid-Schiff (PAS) staining.

[0036] FIG. 6A to FIG. 6D demonstrate total serum IgE levels (ng / mL, FIG. 6A), eotaxin / CCL11 levels (pg / mL) in bronchoalveolar lavage fluid (BALF, FIG. 6B), total BAL counts (FIG. 6C), and eosinophil cell counts in BAL fluid (FIG. 6D) in mice treated with 1 mg / kg, 5 mg / kg, or 25 mg / kg of an exemplary anti-IL-13 antibody of the present disclosure (Antibody AbAE), reference antibody (Ref1), or isotype control (Isotype) and dosed with hlL-13 according to the schedule depicted in FIG. 5. ns = not significant, *** p < 0.001, **** p < 0.0001.

[0037] FIG. 7A and FIG. 7B depict representative images of lung sections and inflammatory endpoint histological scores collected from mice dosed according to the schedule depicted in FIG.5. FIG. 7A shows micrographs of Periodic acid-Schiff (PAS)-stained lung sections collected from mice treated with 1 mg / kg, 5 mg / kg, or 25 mg / kg of an exemplary anti-IL-13 antibody of the present disclosure (Antibody AbAE), reference antibody (Ref1), or isotype control (Isotype) and dosed with hlL-13. FIG. 7B shows PAS scores in lung sections collected from mice treated with 1 mg / kg, 5 mg / kg, or 25 mg / kg of an exemplary anti-IL-13 antibody of the present disclosure (Antibody AbAE), reference antibody (Ref1), or isotype control (Isotype) and dosed with hlL-13. * p < 0.05, **p< 0.01, **** p < 0.0001.

[0038] FIG. 8 shows a heat map produced by measuring binding in real time using biolayer interferometry (BLI) to determine whether Antibody AbG and Ref1 compete for binding on human IL-13. In the heat map, shaded cells indicate bidirectional, blocking, non-binding interactions (response <0.1 nm) and unshaded cells indicate bidirectional, non-blocking, binding interactions (>0.1 nm).

[0039] FIG. 9 shows the normalized responses of Antibody AbAB, Ref2, isotype-hlgG1, and isotype-hlgG1-YTE-TM binding to a panel of recombinant human Fey receptors at 10,000 nM.Attorney Docket No: 134524-5009- WOAntibody binding responses were normalized to human Fey receptor capture levels and reported as normalized binding responses of one experiment.

[0040] FIG. 10 shows the normalized responses of human C1q binding to Antibody AbAB, Ref2, isotype-hlgG4, isotype-hlgG1, and isotype-hlgG1-YTE-TM. The dotted line is positioned at 0.1 nm to indicate a non-binding interaction (< 0.1 nm) from a binding interaction (> 0.1 nm).

[0041] FIG. 11 depicts a multiple sequence alignment of molecules that are near in sequence space (at most 4 mutations) to Antibody AbG but do not bind IL-13 with high affinity. The concatenated CDRs are shown on the top, with any mutations displayed in the alignment below corresponding to the antibody name.

[0042] FIG. 12 shows the mean serum concentration in µg / mL of Antibody AbAB administered at a dose of 300 mg, 600 mg, or 1200 mg over 20 weeks in healthy human subjects (n=6 per dose level). Solid lines depict publicly available data for serum concentration in µg / mL of Ref4 administered at the same dose level over 20 weeks in healthy human subjects (n=6 per dose level). Error bars represent standard error of the mean.

[0043] FIG. 13 shows the mean serum concentration in µg / mL of Antibody AbAB administered at a dose of 300 mg, 600 mg, or 1200 mg over 20 weeks in healthy human subjects (n=6 per dose level). Error bars represent standard error of the mean.DETAILED DESCRIPTION

[0044] The present disclosure provides anti-IL-13 antibodies, or antigen-binding fragments thereof, or compositions comprising anti-IL-13 antibodies, or antigen-binding fragments thereof, for use in the treatment of inflammatory diseases in a subject.

[0045] Several aspects of the disclosure are described below, with reference to examples for illustrative purposes only. It should be understood that numerous specific details, relationships, and methods are set forth to provide a full understanding of the disclosure. One having ordinary skill in the relevant art, however, will readily recognize that the disclosure can be practiced without one or more of the specific details or practiced with other methods, protocols, reagents, cell lines and animals. The disclosure is not limited by the illustrated ordering of acts or events, as some acts may occur in different orders and / or concurrently with other acts or events. Furthermore, not all illustrated acts, steps or events are required to implement a methodology in accordance with the disclosure. Many of the techniques and procedures described, or referenced herein, are well understood and commonly employed using conventional methodology by those skilled in the art.Attorney Docket No: 134524-5009- WOI. Definitions

[0046] Unless otherwise defined, all terms of art, notations and other scientific terms or terminology used herein are intended to have the meanings commonly understood by those of skill in the art to which this disclosure pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and / or as otherwise defined herein.

[0047] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0048] When introducing elements disclosed herein, the articles “a,” “an,” “the,” and “said” are intended to mean that there are one or more of the elements. Further, the one or more elements may be the same or different. For example, unless the context clearly indicates otherwise, “a polypeptide” includes a single polypeptide, and two or more polypeptides.

[0049] Throughout this specification and the claims which follow, unless the context requires otherwise, the term “comprise,” and variations such as “comprises” and “comprising,” will be understood to imply the inclusion of, e.g., a stated integer or step or group of integers or steps, but not the exclusion of any other integer or step or group of integer or step. When used herein, the term “comprising” can be substituted with the term “containing” or “including.”

[0050] As used herein, the term “consisting of’ excludes any element, step, or ingredient not specified in the claim element. When used herein, the term “consisting essentially of’ does not exclude materials or steps that do not materially affect the basic and novel characteristics of the claim.

[0051] Also provided herein are corresponding embodiments for each and every embodiment featuring the term “comprising,” “containing,” “including,” or “having,” wherein those terms are replaced by the term “consisting of’ and / or “consisting essentially of.”

[0052] As used herein, the conjunctive term “and / or” between multiple recited elements is understood as encompassing both individual and combined options. For instance, where two elements are conjoined by “and / or,” a first option refers to the applicability of the first element without the second. A second option refers to the applicability of the second element without the first. A third option refers to the applicability of the first and second elements together. Any one ofAttorney Docket No: 134524-5009- WOthese options is understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and / or” as used herein. Concurrent applicability of more than one of the options is also understood to fall within the meaning, and, therefore, satisfy the requirement of the term “and / or.”

[0053] It should be understood that for all numerical bounds describing some parameter in this application, such as “about,” “at least,” “less than,” “fewer than,” and “more than,” the description also necessarily encompasses any range bounded by the recited values. Accordingly, for example, the description “at least 1, 2, 3, 4, or 5” also describes, inter alia, the ranges 1-2, 1-3, 1-4, 1-5, 2-3, 2-4, 2-5, 3-4, 3-5, and 4-5, et cetera.

[0054] When a list is presented, unless stated otherwise, it is to be understood that each individual element of that list, and every combination of that list, is a separate embodiment. For example, a list of embodiments presented as “A, B, or C” is to be interpreted as including the embodiments, “A,” “B,” “C,” “A or B,” “A or C,” “B or C,” or “A, B, or C.”

[0055] As used herein, the term “about” means within an acceptable error range for a particular value, as determined by one of ordinary skill in the art. Typically, an acceptable error range for a particular value depends, at least in part, on how the value is measured or determined, e.g., the limitations of the measurement system. For example, “about” can mean within an acceptable standard deviation, per the practice in the art. Alternatively, “about” can mean a range of ±20%, e.g., ±10%, ±5% or ±1% of a given value. It is to be understood that the term “about” can precede any particular value specified herein, except for particular values used in the Exemplification. When “about” precedes a range, as in “90-99.9%,” the term “about” should be read as applying to both given values of the range, such that “about 90-99.9%” means about 90% repeats to about 99.9%.

[0056] As used herein, the term “polypeptide” refers to a polymer of at least two amino acids covalently linked by an amide bond, regardless of length or post-translational modification (e.g., glycosylation or phosphorylation). A polypeptide can comprise any suitable L- and / or D-amino acid, for example, common a-amino acids (e.g., alanine, glycine, valine), non-a-amino acids (e.g., P-alanine, 4-aminobutyric acid, 6-aminocaproic acid, sarcosine, statine), and unusual amino acids (e.g., citrulline, homocitruline, homoserine, norleucine, norvaline, ornithine). The amino, carboxyl, and / or other functional groups on a polypeptide can be free (e.g., unmodified) or protected with a suitable protecting group. Suitable protecting groups for amino and carboxyl groups, and methods for adding or removing protecting groups are known in the art and are disclosed in, for example, Green and Wuts, “Protecting Groups in Organic Synthesis,” John Wiley and Sons, 1991. The functional groups of a polypeptide can also be derivatized (e.g., alkylated) or labeled (e.g., with aAttorney Docket No: 134524-5009- WOdetectable label, such as a fluorogen or a hapten) using methods known in the art. A polypeptide can comprise one or more modifications (e.g., amino acid linkers, acylation, acetylation, amidation, methylation, terminal modifiers (e.g., cyclizing modifications), N-methyl-a-amino group substitution), if desired. In addition, a polypeptide can be an analog of a known and / or naturally occurring peptide, for example, a peptide analog having conservative amino acid residue substitution(s).

[0057] As used herein, a “polynucleotide” is defined as a plurality of nucleotides and / or nucleotide analogs linked together in a single molecule. In some embodiments, a polynucleotide disclosed herein comprises deoxyribonucleotides. In some embodiments, the polynucleotide comprises ribonucleotides. Non-limiting examples of polynucleotides include single-, double- or multi-stranded DNA or RNA, DNA-RNA hybrids (e.g., each “T” position may be independently substituted by a “U” or vice versa), ora polymer comprising purine and pyrimidine bases, or other natural, chemically, or biochemically modified, non-natural, or derivatized nucleotide bases. The backbone of the polynucleotide can comprise sugars and phosphate groups, modified or substituted sugar or phosphate groups, a polymer of synthetic subunits such as phosphoramidates, or a combination thereof.

[0058] As used herein, the term “sequence identity” refers to the extent to which two nucleotide sequences have the same residues at the same positions when the sequences are aligned to achieve a maximal level of identity, expressed as a percentage. For sequence alignment and comparison, typically one sequence is designated as a reference sequence, to which test sequences are compared. Sequence identity between reference and test sequences is expressed as a percentage of positions across the entire length of the reference sequence where the reference and test sequences share the same nucleotide or amino acid upon alignment of the reference and test sequences to achieve a maximal level of identity. As an example, two sequences are considered to have 70% sequence identity when, upon alignment to achieve a maximal level of identity, the test sequence has the same nucleotide residue at 70% of the same positions over the entire length of the reference sequence.

[0059] Alignment of sequences for comparison to achieve maximal levels of identity can be readily performed by a person of ordinary skill in the art using an appropriate alignment method or algorithm. In some instances, alignment can include introduced gaps to provide for the maximal level of identity. Examples include the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol.48:443 (1970), the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USAAttorney Docket No: 134524-5009- WO85:2444 (1988), computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), and visual inspection (see generally Ausubel et. al., Current Protocols in Molecular Biology).

[0060] When using a sequence comparison algorithm, test and reference sequences are input into a computer, subsequent coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters. A commonly used tool for determining percent sequence identity is Protein Basic Local Alignment Search Tool (BLASTP) available through National Center for Biotechnology Information, National Library of Medicine, of the United States National Institutes of Health. (Altschul et. al., 1990).

[0061] As used herein, the term “substantially similar to” refers to a polypeptide disclosed herein that is substantially similar in amino acid sequence (e.g., has at least about 80%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the amino acid residues amino acid sequence identity) and substantially preserves one or more functional properties of a specified polypeptide disclosed herein (e.g., AB-1). In some embodiments, the one or more functional properties are selected from, without limitation, a substantially similar binding affinity, a substantially similar binding specificity, a substantially similar inhibitory activity, a substantially similar neutralization activity, and a substantially similar self-association property.

[0062] The term “monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, e.g., the individual antibodies comprising the population are identical and / or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations and / or arising during production of a monoclonal antibody preparation (e.g., variants having a C-terminal lysine deletion). In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies and is not to be construed as requiring production of the antibody by any method. For example, the monoclonal antibodies to be used may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage display methods, andAttorney Docket No: 134524-5009- WOmethods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

[0063] The term “chimeric” antibody refers to a recombinant antibody in which a portion of the heavy and / or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species, or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity. In addition, complementarity determining region grafting may be performed to alter certain properties of the antibody molecule including affinity or specificity. Typically, the variable domains are obtained from an antibody from an experimental animal (the "parental antibody"), such as a rodent, and the constant domain sequences are obtained from human antibodies, so that the resulting chimeric antibody can direct effector functions in a human subject and will be less likely to elicit an adverse immune response than the parental (e.g., mouse) antibody from which it is derived.

[0064] The term “humanized antibody” refers to an antibody that has been engineered to comprise one or more human framework regions in the variable region together with non-human (e.g., mouse, rat, or hamster) complementarity-determining regions of the heavy and / or light chain. In some embodiments, a humanized antibody comprises sequences that are entirely human except for the CDR regions. Humanized antibodies are typically less immunogenic to humans, relative to non-humanized antibodies, and thus offer therapeutic benefits in certain situations. Many examples exist of humanized antibodies and suitable techniques for their generation. See for example, Hwang et. al., Methods. 36:35, 2005; Queen et. al., Proc. Natl. Acad. Sci. USA. 86:10029-10033, 1989; Jones et. al., Nature. 321:522-25, 1986, Riechmann et. al., Nature. 332:323-27, 1988; Verhoeyen et. al., Science. 239:1534-36, 1988; Orlandi et. al., Proc. Natl. Acad. Sci. USA. 86:3833-37, 1989; U. S. Pat. Nos. 5,225,539; 5,530,101; 5,585,089; 5,693,761, 5,693,762; 6,180,370; and Selick et. al. (WO 90 / 07861), each of which is incorporated herein by reference in its entirety.

[0065] A “human antibody” is an antibody that possesses an amino-acid sequence corresponding to that of an antibody capable of being produced by the human genome and / or has been made using any of the techniques for making human antibodies. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigenbinding residues. Human antibodies can be produced using various techniques, includingAttorney Docket No: 134524-5009- WOmethods described in Cole et. al., Monoclonal Antibodies and Cancer Therapy. 27:77-96, 1985; Boemer et. al., J. Immuno. 147(1):86-95; 1991. See also van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5:368-74; 2001. Human antibodies can be prepared by administering the antigen to a transgenic animal that has been modified to produce such antibodies in response to antigenic challenge, but whose endogenous loci have been disabled, e.g., immunized HuMab mice (see, e.g., Lonberg et. al., Nature. 368:856-859, 1994; WO 98 / 24884; WO 94 / 25585; WO 92 / 22645; U. S. Pat. No. 5,569,825 (WO 92 / 03918); and U. S. Pat. App. No. 10 / 031,722 (WO 01 / 09187) regarding HuMab mice), xenomice (see, e.g., U. S. Pat. Nos. 5,569,825, 6,075,181 and 6,150,584 regarding XENOMOUSE™ technology).

[0066] The “class” of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., lgG1, lgG2, lgG3, lgG4, lgA1, and lgA2. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α, δ, ε, γ, and µ, respectively.

[0067] The terms “antigen-binding domain” of an antibody (or simply “binding domain”) of an antibody or similar terms refer to one or more fragments of an antibody that retain the ability to specifically bind to an antigen complex. Examples of binding fragments encompassed within the term “antigen-binding portion” of an antibody include (i) Fab fragments, monovalent fragments consisting of the VL, VH, constant light (CL) and constant heavy (CH) domains; (ii) F(ab’)2fragments, bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; (iii) Fd fragments consisting of the VH and CH domains; (iv) Fv fragments consisting of the VL and VH domains of a single arm of an antibody, (v) dAb fragments (Ward et. al., Nature.341: 544-546; 1989), which consist of a VH domain; (vi) isolated complementarity determining regions, and (vii) combinations of two or more isolated CDRs which may optionally be joined by a synthetic linker.

[0068] The “variable domain” (V domain) or “variable region” of an antibody mediates binding and confers antigen specificity of a particular antibody. However, the variability is not evenly distributed across the 110-amino acid span of the variable domains. Instead, the V regions consist of relatively invariant stretches called framework regions of 15-30 amino acids separated by shorter regions of extreme variability referred to herein as “hypervariable regions” or CDRs that are each 9-12 amino acids long. The exact numbering and placement of the CDRs can be different among different numbering systems. However, a variable heavy and / or variable light sequence includes the associated CDRs. Accordingly, each variable heavy region includes the vhCDRsAttorney Docket No: 134524-5009- WO(e.g., vhCDR1 (also referred to herein as HCDR1), vhCDR2 (also referred to herein as HCDR2), and vhCDR3 (also referred to herein as HCDR3)) and each variable light region includes the vlCDRs (e.g., vlCDR1 (also referred to herein as LCDR1), vlCDR2 (also referred to herein as LCDR2), and vlCDR3 (also referred to herein as LCDR3)).

[0069] As used herein, a “complementarity determining region (CDR)” encompasses any CDR defined by an art-recognized method for identifying the CDR residues on an antibody. See, e.g., Kabat, E. A., et. al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U. S. Department of Health and Human Services, NIH Publication No. 91-3242, Chothia et. al., (1989) Nature 342:877; Chothia, C. et. al., (1987) J. Mol. Biol. 196:901-917; Al-lazikani et. al., (1997) J. Molec. Biol. 273:927-948; and Almagro, J. Mol. Recognit. 17:132-143 (2004). See also hgmp.mrc.ac.uk and bioinf.org.uk / abs. Two antibodies are determined to have the same CDR as one another with respect to a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and / or LCDR3, when the identity of that CDR is determined for both antibodies using the same method.

[0070] “Framework” or “framework region” or “FR” refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4.

[0071] The extent of the framework region and the CDRs of an antibody can be identified using one of several suitable methodologies that are well known in the art, for example, by the Kabat definition, the Chothia definition, the AbM definition, and / or the contact definition. Publicly and / or commercially available tools for identifying framework and / or CDR regions include, IgBlast (accessible at www.ncbi.nlm.nih.gov / igblast / ), Scaligner (available from drugdesigntech at www.scaligner.com / ), IMGT rules and / or tools (see, for example, www.imgt.org / IMGTScientificChart / Nomenclature / IMGT-FRCDRdefinition.html, also accessible at www.imgt.org / ), Chothia Canonical Assignment (accessible at www.bioinforg.uk / abs / chothia.html), Antigen receptor Numbering And Receptor Classification (ANARCI, accessible at opig.stats.ox.ac.uk / webapps / newsabdab / sabpred / anarci / ), or the Paratome web server (accessible at www.ofranlab.org / paratome / , or the Paratome web server (accessible at www.ofranlab.org / paratome / see Vered Kunik, et al, Nucleic Acids Research, Volume 40, Issue W1, 1 Jul. 2012, Pages W521-W524).

[0072] In some embodiments, the CDRs of an antibody can be determined according to MacCallum et. al., J Mol Biol. 262:732-745; 1996, herein incorporated by reference in its entirety or according to the IMGT numbering system as described in Lefranc, The Immunologist. 7:132-136; 1999 and Lefranc et. al., Nucleic Acids Res. 27: 209-212;1999, each of which is hereinAttorney Docket No: 134524-5009- WOincorporated by reference in its entirety. See also, e.g., Martin et. al., Antibody Engineering.31:422-439; 2001, herein incorporated by reference in its entirety. In some embodiments, the CDRs of an antibody can be determined according to the AbM numbering scheme, which refers to AbM hypervariable regions, which represent a compromise between the Kabat CDRs and Chothia structural loops and are used by Oxford Molecular's AbM antibody modeling software (Oxford Molecular Group, Inc.), herein incorporated by reference in its entirety.

[0073] As used herein, all numbering is determined by EU index numbering as in Kabat, unless otherwise indicated.

[0074] A “human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally, the subgroup of sequences is a subgroup as in Kabat et. al., NIH. 1:103-108, 324-331; 1991. In some embodiments, for the VL, the subgroup is subgroup kappa I as in Kabat et. al., supra. In some embodiments, for the VH, the subgroup is subgroup III as in Kabat et. al., supra.

[0075] The “hinge region” is generally defined as stretching from 216-238 (EU numbering) or 226-251 (Kabat numbering) of human lgG1. The hinge can be further divided into three distinct regions, the upper, middle (e.g., core), and lower hinge.

[0076] The term “Fc region” herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In some embodiments, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447) of the Fc region may or may not be present. Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et. al., supra.

[0077] An “antibody that binds to the same epitope” as a reference antibody (e.g., a reference IL- 13 antibody) refers to an antibody that contacts an overlapping set of amino acid residues of the antigen as compared to the reference antibody or blocks binding of the reference antibody to its antigen in a competition assay by at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, or more. The amino acid residues of an antibody that contact an antigen can be determined,Attorney Docket No: 134524-5009- WOfor example, by determining the crystal structure of the antibody in complex with the antigen or by performing hydrogen / deuterium exchange. In some embodiments, residues of an antibody that are within 5 A to the antigen are considered to contact the antigen. In some embodiments, residues of an antibody that are within 4 A to the antigen are considered to contact the antigen. In some embodiments, residues of an antibody that make a non-covalent interaction with one or more residues of the antigen are considered to contact the antigen, including but not limited to hydrogen bonds, van der Waals interactions, salt bridges, Pi stacking interactions, hydrophobic interactions, or water-mediated hydrogen bonds.

[0078] An "epitope" indicates the site or sites of interaction between an antibody and its antigen(s). As described by (Janeway, C, Jr., P. Travers, et. al., (2001). Immunobiology: the immune system in health and disease. Part II, Section 3-8. New York, Garland Publishing, Inc.): " An antibody generally recognizes only a small region on the surface of a large molecule such as a protein... [Certain epitopes] are likely to be composed of amino acids from different parts of the [antigen] polypeptide chain that have been brought together by protein folding. Antigenic determinants of this kind are known as conformational or discontinuous epitopes because the structure recognized is composed of segments of the protein that are discontinuous in the amino acid sequence of the antigen but are brought together in the three-dimensional structure. In contrast, an epitope composed of a single segment of polypeptide chain is termed a continuous or linear epitope" (Janeway, C. Jr., P. Travers, et. al., (2001). Immunobiology: the immune system in health and disease. Part II, Section 3-8. New York, Garland Publishing, Inc.). An epitope may be a structural epitope or a functional epitope.

[0079] In some embodiments, an antibody that binds to the same epitope as a reference antibody blocks binding of the reference antibody to its antigen in a competition assay by at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, or more.

[0080] As used herein, the term “paratope” refers to a set of amino acid residues in an antibody or an antigen-binding fragment thereof that contribute to a binding interaction with an epitope of a target protein. The binding interaction can be a hydrogen bond, a salt bridge, a van der Waal interaction, an ionic bond, or a combination thereof. A binding interaction may be direct, or indirect, e.g., via a coordinated intermediate molecule, such as an ion or water. The residuesAttorney Docket No: 134524-5009- WOof a paratope, in some embodiments, comprise only residues that are part of a defined CDR. In other embodiments, the residues of a paratope further comprise one or more residues that are not part of a defined CDR.

[0081] The term “antigen binding fragment” or “antibody fragment” refers to a molecule other than an intact antibody (e.g., a full-length antibody) that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antigen binding fragments include but are not limited to Fv, Fab, Fab’, Fab’-SH, F(ab)2; diabodies; linear antibodies; singlechain antibody molecules e.g., scFv). Papain digestion of antibodies produces two identical antigen-binding fragments, called “Fab” fragments, and a residual “Fc” fragment, a designation reflecting the ability to crystallize readily. The Fab fragment consists of an entire light (L) chain along with the variable region domain of the heavy (H) chain (VH), and the first constant domain of one heavy chain (CHI). Pepsin treatment of an antibody yields a single large F(ab)2 fragment which roughly corresponds to two disulfide linked Fab fragments having divalent antigen-binding activity and is still capable of cross-linking antigen. Fab fragments differ from Fab’ fragments by having additional few residues at the carboxy terminus of the CHI domain including one or more cysteines from the antibody hinge region. Fab’-SH is the designation herein for Fab’ in which the cysteine residue(s) of the constant domains bear a free thiol group. F(ab’)2antigen binding fragments originally were produced as pairs of Fab’ fragments which have hinge cysteines between them. Other chemical couplings of antigen binding fragments are also known.

[0082] “Fv” consists of a dimer of one heavy- and one light-chain variable region domain in tight, non-covalent association. From the folding of these two domains emanate six hypervariable loops (3 loops each from the H and L chain) that contribute the amino acid residues for antigen binding and confer antigen binding specificity to the antibody.

[0083] “Single-chain Fv” also abbreviated as “sFv” or “scFv” are antigen binding fragments that comprise the VH and VL antibody domains connected into a single polypeptide chain. The sFv polypeptide may further comprise a linker (e.g., a polypeptide linker) between the VH and VL domains which enables the sFv to form the desired structure for antigen binding. For a review of sFv, see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269- 315 (1994).

[0084] As used herein, the term “antibody mimetic” refers to polypeptides capable of mimicking an antibody's ability to bind an antigen, but structurally differ from native antibody structures. Examples of antibody mimetics include, but not limited to, Adnectins, Affibodies,Attorney Docket No: 134524-5009- WOAffilins, Affimers, Affitins, Alphabodies, Anticalins, Avimers, DARPins, Fynomers, Kunitz domain peptides, monobodies, nanobodies, nanoCLAMPs, and Versabodies.

[0085] The term an “isolated antibody” or an “isolated antigen binding fragment” when used to describe the various antibodies or antigen binding fragments thereof provided herein, means an antibody or antigen binding fragment that has been identified and separated and / or recovered from a cell or cell culture from which it was expressed. An isolated antibody or antigen binding fragment may include variants of the antibody or antigen binding fragment having one or more co- or post-translational modifications that arise during production, purification, and / or storage of the antibody or antigen binding fragment Contaminant components of its natural environment are materials that would typically interfere with diagnostic or therapeutic uses for the polypeptide, and can include enzymes, hormones, and other proteinaceous or non-proteinaceous solutes. In some embodiments, an isolated antibody is purified to greater than 95%, 96%, 97%, 98%, or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC) approaches. For a review of methods for assessment of antibody purity, see, for example, Flatman et. al., J Chromatogr. 848:79-87; 2007. In some embodiments, the antibody will be purified (1) to a degree sufficient to obtain at least 15 residues of N-terminal or internal amino acid sequence by use of a spinning cup sequenator, or (2) to homogeneity by SDS-PAGE under nonreducing or reducing conditions using Coomassie blue or silver stain.

[0086] With regards to the binding of an antibody to a target molecule, the term “specific binding” or “specifically binds” or is “specific for” a particular polypeptide or protein such as IL-13 or an epitope on a particular polypeptide or protein target such as IL-13 means binding that is measurably different from a non-specific interaction. Specific binding can be measured, for example, by determining binding of a molecule compared to binding of a control molecule. For example, specific binding can be determined by competition with a control molecule that is similar to the target, for example, an excess of non-labeled target. In this case, specific binding is indicated if the binding of the labeled target to a probe is competitively inhibited by excess unlabeled target (e.g., inhibited by at least about 10%, about 10%, at least about 20%, about 20%, at least about 30%, about 30%, at least about 40%, about 40%, at least about 50%, about 50%, at least about 60%, about 60%, at least about 70%, about 70%, at least about 80%, about 80%, at least about 90%, about 90%, at least about 100%, or about 10%). The term “specific binding” or “specifically binds to” or is “specific for” a particular polypeptide or an epitope on a particular polypeptide target as used herein can be exhibited, for example, by a molecule having a KD forAttorney Docket No: 134524-5009- WOthe target of 10’4M or lower, alternatively 10-5M or lower, alternatively 10-5M or lower, alternatively 10’7M or lower, alternatively 10-8M or lower, alternatively 10-9M or lower, alternatively 10’10M or lower, alternatively 10-11M or lower, alternatively 10-12M or lower or a KDin the range of 10-4M to 10-6M or 10’6M to 10-10M or 10-7M to 10-9M. Affinity and KDvalues are inversely related. A high affinity for an antigen is measured by a low Kovalue. In some embodiments, the term “specific binding” refers to binding where a molecule binds to IL- 13 or to an IL-13 epitope without substantially binding to any other polypeptide or polypeptide epitope. As used herein, the term “binding” may refer to “specific binding” such that each and every occurrence of the term “binding” may be replaced with the term “specific binding.”

[0087] The term “affinity” as used herein, means the strength of the binding of an antibody to an epitope. The affinity of an antibody is given by the equilibrium dissociation constant KD, defined as [Ab]x[Ag] / [Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of the unbound antibody and [Ag] is the molar concentration of the unbound antigen. The affinity constantis defined by 1 / D. Methods for determining the affinity of monoclonal antibodies (mAbs) can be found in Harlow, et. al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory' Press, Cold Spring Harbor, N. Y., (1988), Coligan et. al., Current Protocols in Immunology, Greene Publishing Assoc, and Wiley Interscience, N. Y., (1992, 1993), and Muller, Meth. Enzymol. 92:589-601; 1983, which are entirely incorporated herein by reference. One standard method for determining the affinity of mAbs is the use of surface plasmon resonance (SPR) screening (such as by analysis with a BIAcore™ SPR analytical device).

[0088] As used herein the term “KD,” also referred to as “binding constant,” “equilibrium dissociation constant” or “affinity constant,” is a measure of the extent of a reversible association between two molecular species (e.g., antibody and target protein) and includes both the actual binding affinity as well as the apparent binding affinity. Binding affinity can be determined using methods known in the art including, for example, by measurement of surface plasmon resonance, e.g., using a Biolayer interferometry (Octet, ForteBio) or a surface plasmon resonance (Biacore) system and assay. A reference that compares various surface technologies for measuring binding affinity and kinetics is Yang, D., Singh, A., Wu, H., & Kroe-Barrett, R., Comparison of biosensor platforms in the evaluation of high affinity antibody-antigen binding kinetics, Analytical Biochemistry 508: 78-96 (2016), the contents of which are incorporated by reference herein in their entirety.

[0089] “ECso” with respect to an agent and a particular activity (e.g., binding to a cell, inhibition of enzymatic activity, activation, or inhibition of an immune cell), refers to the efficientAttorney Docket No: 134524-5009- WOconcentration of the agent which produces 50% of its maximum response or effect with respect to such activity. “EC100” with respect to an agent and a particular activity refers to the efficient concentration of the agent which produces its substantially maximum response with respect to such activity.

[0090] “IC50” with respect to an agent and a particular activity (e.g., binding to a cell, inhibition of enzymatic activity, activation, or inhibition of an immune cell), refers to the inhibitory concentration of the agent which inhibits half of its maximum response or effect with respect to such activity. “IC100” with respect to an agent and a particular activity refers to the inhibitory concentration of the agent which inhibits its substantially maximum response with respect to such activity.

[0091] The term “subject” or “patient” refers to an animal (e.g., a mammal such as a human), diagnosed with or suspected of having an IL-13-associated disease or condition (e.g., a disease or condition associated with dysregulated IL-13 expression such as asthma or atopic dermatitis (AD)), or one at risk of developing such conditions. Diagnosis may be performed by any method or technique known in the art. One skilled in the art will understand that a subject to be treated according to the present disclosure may have been subjected to standard tests or may have been identified, without examination, as one at risk due to the presence of one or more risk factors associated with the disease or condition.

[0092] The phrase “pharmaceutically acceptable” means that the substance or composition the phrase modifies is, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio.

[0093] As used herein, the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals without undue toxicity, irritation, allergic response, and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known. For example, S. M. Berge et. al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, the relevant teachings of which are incorporated herein by reference in their entirety. Pharmaceutically acceptable salts of the agents / compounds described herein include salts derived from suitable inorganic and organic acids, and suitable inorganic and organic bases.Attorney Docket No: 134524-5009- WO

[0094] Examples of salts derived from suitable acids include salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other known methods, such as ion exchange. Other pharmaceutically acceptable salts derived from suitable acids include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cinnamate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, glutarate, glycolate, hemisulfate, heptanoate, hexanoate, hydroiodide, hydroxy benzoate, 2-hydroxy-ethanesulfonate, hydroxymaleate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 2-phenoxybenzoate, phenylacetate, 3-phenylpropionate, phosphate, pivalate, propionate, pyruvate, salicylate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.

[0095] Either the mono-, di- or tri-acid salts can be formed, and such salts can exist in either a hydrated, solvated, or substantially anhydrous form.

[0096] Salts derived from appropriate bases include salts derived from inorganic bases, such as alkali metal, alkaline earth metal, and ammonium bases, and salts derived from aliphatic, alicyclic, or aromatic organic amines, such as methylamine, trimethylamine and picoline, or N+((C1-C4)alkyl)4 salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, barium and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxyl, sulfate, phosphate, nitrate, lower alkyl sulfonate, and aryl sulfonate.

[0097] “Pharmaceutically acceptable carrier” refers to a non-toxic carrier or excipient that does not destroy the pharmacological activity of the agent with which it is formulated and is nontoxic when administered in doses sufficient to deliver a therapeutic amount of the agent. Pharmaceutically acceptable carriers that may be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogenAttorney Docket No: 134524-5009- WOphosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol, and wool fat.

[0098] “Treating” or “treatment,” as used herein, refers to taking steps to deliver a therapy to a subject, such as a mammal, in need thereof (e.g., as by administering to a mammal one or more therapeutic agents). “Treating” or “treatment” includes inhibiting the disease or condition (e.g., as by slowing or stopping its progression or causing regression of the disease or condition) and relieving the symptoms resulting from the disease or condition.

[0099] The term “treating,” or “treatment” refers to the medical management of a subject with the intent to improve, ameliorate, stabilize (e.g., not worsen), prevent, or cure a disease, pathological condition, or disorder-such as the particular indications exemplified herein. This term includes active treatment (treatment directed to improve the disease, pathological condition, or disorder), causal treatment (treatment directed to the cause of the associated disease, pathological condition, or disorder), palliative treatment (treatment designed for the relief of symptoms), preventative treatment (treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder); and supportive treatment (treatment employed to supplement another therapy). Treatment also includes diminishment of the extent of the disease or condition; preventing spread of the disease or condition; delay or slowing the progress of the disease or condition; amelioration or palliation of the disease or condition; and remission (whether partial or total), whether detectable or undetectable. “Ameliorating” or “palliating” a disease or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment. “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment. Those in need of treatment include those already with the condition or disorder, as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

[0100] A “pharmaceutical composition” refers to a formulation of one or more therapeutic agents and a medium generally accepted for delivery of a biologically active agent to subjects, e.g., humans. In some embodiments, a pharmaceutical composition may include one or more pharmaceutically acceptable excipients, diluents, or carriers. In some embodiments, aAttorney Docket No: 134524-5009- WOpharmaceutical composition suitable for use in methods disclosed herein further comprises one or more pharmaceutically acceptable carriers.

[0101] “Pharmaceutically acceptable carrier, diluent, or excipient” includes any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye / colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.

[0102] “Pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical composition, other than an active ingredient, which is nontoxic to a subject A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative. In some embodiments, the carrier may be a diluent, adjuvant, excipient, or vehicle with which the agent (e.g., polynucleotide) is administered. Such vehicles may be liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. For example, 0.4% saline and 0.3% glycine can be used. These solutions are sterile and generally free of particulate matter. They may be sterilized by conventional, well-known sterilization techniques (e.g., filtration). The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, stabilizing, thickening, lubricating, and coloring agents, etc. The concentration of the agent in such pharmaceutical formulation may vary widely, e.g., from less than about 0.5%, to at least about 1 %, or to as much as 15% or 20%, 25%, 30%, 35%, 40%, 45% or 50% by weight. The concentration will be selected primarily based on required dose, fluid volumes, viscosities, etc., according to the mode of administration. Suitable vehicles and formulations, inclusive of other human proteins, e.g., human serum albumin, are described, for example, in Remington: The Science and Practice of Pharmacy, 21st Edition, Troy, D. B. ed., Lipincott Williams and Wilkins, Philadelphia, PA 2006, Part 5, Pharmaceutical Manufacturing: 691-1092 (e.g., pages 958-89).

[0103] Non-limiting examples of pharmaceutically acceptable carriers are solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible, such as salts, buffers, antioxidants, saccharides, aqueous or non-aqueous carriers, preservatives, wetting agents, surfactants or emulsifying agents, or combinations thereof.Attorney Docket No: 134524-5009- WO

[0104] Non-limiting examples of buffers are acetic acid, citric acid, formic acid, succinic acid, phosphoric acid, carbonic acid, malic acid, aspartic acid, histidine, boric acid, Tris buffers, HEPPSO, and HEPES.

[0105] Non-limiting examples of antioxidants are ascorbic acid, methionine, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, lecithin, citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, and tartaric acid.

[0106] Non-limiting examples of amino acids are histidine, isoleucine, methionine, glycine, arginine, lysine, L-leucine, tri-leucine, alanine, glutamic acid, L-threonine, and 2-phenylamine.

[0107] Non-limiting examples of surfactants are polysorbates (e.g., polysorbate-20 or polysorbate-80); polyoxamers (e.g., poloxamer 188); Triton; sodium octyl glycoside; lauryl, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl- or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroamidopropyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-betaine (e.g., lauroamidopropyl); myristamidopropyl-, palmidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl-, or disodium methyl oleyl-taurate; and the MONAQUA™ series (Mona Industries, Inc., Paterson, N. J.), polyethyl glycol, polypropyl glycol, and copolymers of ethylene and propylene glycol (e.g., PLURONICS™, PF68, etc.).

[0108] Non-limiting examples of preservatives are phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride, alkylparaben (methyl, ethyl, propyl, butyl, and the like), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal, or mixtures thereof.

[0109] Non-limiting examples of saccharides are monosaccharides, disaccharides, trisaccharides, polysaccharides, sugar alcohols, reducing sugars, nonreducing sugars such as glucose, sucrose, trehalose, lactose, fructose, maltose, dextran, glycerin, dextran, erythritol, glycerol, arabitol, sylitol, sorbitol, mannitol, mellibiose, melezitose, raffinose, mannotriose, stachyose, maltose, lactulose, maltulose, glucitol, maltitol, lactitol, or iso-maltulose.

[0110] Non-limiting examples of salts are acid addition salts and base addition salts. Acid addition salts include those derived from nontoxic inorganic acids, such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydroiodic, phosphorous, and the like, as well as from nontoxic organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, aromatic acids, aliphatic and aromatic sulfonic acids, and the like. BaseAttorney Docket No: 134524-5009- WOaddition salts include those derived from alkaline earth metals, such as sodium, potassium, magnesium, calcium, and the like, as well as from nontoxic organic amines, such as N, N'-dibenzylethylenediamine, N-methylglucamine, chloroprocaine, choline, diethanolamine, ethylenediamine, procaine, and the like. In some embodiments, the salt is sodium chloride (NaCI).

[0111] Agents (e.g., polynucleotides) described herein may be prepared in accordance with standard procedures and are administered at dosages that are selected to reduce, prevent, or eliminate, or to slow or halt progression of, a condition being treated (see, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, and Goodman and Gilman's The Pharmaceutical Basis of Therapeutics, McGraw-Hill, New York, N. Y., the contents of which are incorporated herein by reference, for a general description of methods for administering various agents for human therapy).

[0112] “Administering” or “administration,” as used herein, refers to providing a compound, composition, or pharmaceutically acceptable salt thereof described herein to a subject in need of treatment or prevention. Administering can be performed, for example, once, a plurality of times, and / or over one or more extended periods. Administration includes both direct administration (including self-administration), and indirect administration (including an act of prescribing a drug or directing a subject to consume an agent). For example, as used herein, one (e.g., a physician) who instructs a subject (e.g., a human patient) to self-administer an agent (e.g., a drug), or to have an agent administered by another and / or who provides a patient with a prescription for a drug is administering an agent to a subject.

[0113] “A therapeutically effective amount,” “an effective amount,” or “an effective dosage” refers to an amount effective, at dosages and for periods of time necessary, to achieve a desired therapeutic result (e.g., treatment, healing, inhibition or amelioration of physiological response or condition). A full therapeutic effect does not necessarily occur by administration of one dose and may occur only after administration of a series of doses. Thus, a therapeutically effective amount may be administered in one or more administrations. A therapeutically effective amount may vary according to factors such as the disease state, age, sex, and weight of a mammal (e.g., a human patient), mode of administration, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response.

[0114] Desired response or desired results include effects at the cellular level, tissue level, or clinical results. As such, “a therapeutically effective amount” or synonym thereto depends upon the context in which it is being applied. For example, in some embodiments it is an amount of the composition sufficient to achieve a treatment response as compared to the response obtainedAttorney Docket No: 134524-5009- WOwithout administration of the composition. In other embodiments, it is an amount that results in a beneficial or desired result in a subject as compared to a control.II. Interleukin 13 (IL-13)

[0115] Interleukin 13 (IL-13), which is also known as NC30, is a cytokine that plays important roles in allergic inflammation and immune response to infection. Without wishing to be bound by theory, IL-13 is known to play roles, inter alia, in B-cell proliferation, and activation of eosinophils, basophils, and mast cells, controlling IL-33 activity. Minty et. al., Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses, Nature 362:248-250 (1993); McKenzie et. al., Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and 13-cell function, Proc. Natl. Acad. Sci. U. S. A. 90:3735-3739 (1993); Defrance et. al., Interleukin 13 is a B cell stimulating factor, J. Exp. Med. 179:135-143 (1994); Luttmann et. al., Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability, J. Immunol. 157:1678-1683 (1996), each of which is herein incorporated by reference in its entirety.

[0116] As used herein, Interleukin 13 (IL-13) includes wild-type IL-13 protein (e.g., wild-type human IL-13 protein, an isoform thereof or an orthologs thereof) and a truncated form thereof, mutant, and engineered versions of full-length and truncated IL-13 protein, and modified form (e.g., post-translationally modified forms) of full-length and truncated IL-13 proteins.

[0117] A non-limiting example of amino acid sequence of a precursor of a human IL-13 is publicly available as NCBI Reference Sequence NG_012090.1, which is copied below:MHPLLNPLLLALGLMALLLTTVIALTCLGGFASPGPVPPSTALRELIEELVNITQNQKAPLCNGSM VWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFVK DLLLHLKKLFREGQFN (SEQ ID NO: 161)

[0118] A non-limiting example of amino acid sequence of mature human IL-13 is publicly available as NCBI Reference Sequences NP_001341920.1, NP_001341921.1 and NP_001341922.1, which is copied below:MVWSINLTAGMYCAALESLINVSGCSAIEKTQRMLSGFCPHKVSAGQFSSLHVRDTKIEVAQFV KDLLLHLKKLFREGQFN (SEQ ID NO: 212)

[0119] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to a wild-type IL-13 protein (e.g., an IL-13 protein having an amino acid sequence of SEQ ID NO: 161 and / or SEQ ID NO: 212). In some embodiments, an antibody ofAttorney Docket No: 134524-5009- WOthe present disclosure, or antigen-binding fragment thereof, binds to an IL-13 protein comprising the amino acid sequence of SEQ ID NO: 161. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to an IL-13 protein comprising the amino acid sequence of SEQ ID NO: 212. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to an IL-13 protein comprising the amino acid sequence of SEQ ID NO: 212 and an IL-13 protein comprising the amino acid sequence of SEQ ID NO: 161.

[0120] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to a mutant or engineered IL-13 protein. In some embodiments, a mutant or engineered IL-13 protein comprises an amino acid sequence that has at least about 90% sequence identity to a wildtype IL- 13 protein, for example, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, at least about 99.1%, at least about 99.2%, at least about 99.3%, at least about 99.4%, at least about 99.5%, at least about 99.6%, at least about 99.7%, at least about 99.8%, or at least about 99.9% sequence identity to a wildtype IL-13 protein (e.g., SEQ ID NO: 161 and / or SEQ ID NO: 212). In some embodiments, a mutant or engineered IL- 13 protein comprises an amino acid sequence that has about 90% to about 99.9%, about 90% to about 99.8%, about 92% to about 99.8%, about 92% to about 99.6%, about 94% to about 99.6%, about 94% to about 99.5%, about 95% to about 99.5%, about 95% to about 99.4%, about 96% to about 99.4%, about 96% to about 99.2%, about 97% to about 99.2% or about 97% to about 99% sequence identity to a wildtype IL-13 protein.

[0121] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to a modified IL-13 protein.

[0122] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is capable of binding to one or more epitope residues in an IL-13 protein (e.g., a full-length human IL-13), for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 epitope residues of an IL- 13 protein.III. Exemplary Anti-IL-13 Antibodies

[0123] As used herein, the term "antibody" or “immunoglobulin” refers to a full-length antibody comprising two heavy chains (HCs) and two light chains (LCs) inter-connected by disulfide bonds or multimers thereof (for example, IgM). Each HC comprises a variable domain (VH), a heavy chain constant domain 1 (CH1), a heavy chain constant domain 2 (CH2), and a heavy chainAttorney Docket No: 134524-5009- WOconstant domain 3 (CH3). Each LC comprises a variable domain (VL) and a light chain constant domain (CL). VH and VL domain may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed within framework regions (FRs). Each VH and VL comprises three CDRs and four FRs, arranged from the amino-terminus to the carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0124] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL selected from the group consisting of:(i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 1, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 2, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 3;(ii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 7, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 9;(iii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 13, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 15;(iv) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 19, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 20, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 21;(v) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 25, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 26, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27;(vi) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 31, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 32, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 33;(vii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 37, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 38, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 39;(viii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 43, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 44, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 45;Attorney Docket No: 134524-5009- WO(ix) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 49, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 50, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 51;(x) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 55, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 56, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 57;(xi) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 61, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 62, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 63;(xii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 67, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 68, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 69;(xiii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 73, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 74, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 75;(xiv) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 79, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 80, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 81;(xv) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 85, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 86, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 87;(xvi) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 91, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 92, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 93; and(xvi) HCDR1 comprising an amino acid sequence of SEQ ID NO: 94, HCDR2 comprising an amino acid sequence of SEQ ID NO: 95, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 96; andb) a VH selected from the group consisting of:(i) HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, HCDR2 comprising an amino acid sequence of SEQ ID NO: 5, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 6;(ii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 10, HCDR2 comprising an amino acid sequence of SEQ ID NO: 11, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 12;Attorney Docket No: 134524-5009- WO(iii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 16, HCDR2 comprising an amino acid sequence of SEQ ID NO: 17, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 18;(iv) HCDR1 comprising an amino acid sequence of SEQ ID NO: 22, HCDR2 comprising an amino acid sequence of SEQ ID NO: 23, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 24;(v) HCDR1 comprising an amino acid sequence of SEQ ID NO: 28, HCDR2 comprising an amino acid sequence of SEQ ID NO: 29, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 30;(vi) HCDR1 comprising an amino acid sequence of SEQ ID NO: 34, HCDR2 comprising an amino acid sequence of SEQ ID NO: 35, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 36;(vii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 40, HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 42;(viii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 46, HCDR2 comprising an amino acid sequence of SEQ ID NO: 47, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 48;(ix) HCDR1 comprising an amino acid sequence of SEQ ID NO: 52, HCDR2 comprising an amino acid sequence of SEQ ID NO: 53, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 54;(x) HCDR1 comprising an amino acid sequence of SEQ ID NO: 58, HCDR2 comprising an amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 60;(xi) HCDR1 comprising an amino acid sequence of SEQ ID NO: 64, HCDR2 comprising an amino acid sequence of SEQ ID NO: 65, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 66;(xii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 70, HCDR2 comprising an amino acid sequence of SEQ ID NO: 71, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 72;(xiii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 76, HCDR2 comprising an amino acid sequence of SEQ ID NO: 77, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 78;Attorney Docket No: 134524-5009- WO(xiv) HCDR1 comprising an amino acid sequence of SEQ ID NO: 82, HCDR2 comprising an amino acid sequence of SEQ ID NO: 83, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 84;(xv) HCDR1 comprising an amino acid sequence of SEQ ID NO: 88, HCDR2 comprising an amino acid sequence of SEQ ID NO: 89, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 90.

[0125] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL selected from the group consisting of:(i) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 1, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 2, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 3;(ii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 7, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 9;(iii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 13, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 15;(iv) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 19, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 20, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 21;(v) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 25, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 26, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27;(vi) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 31, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 32, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 33;(vii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 37, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 38, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 39;(viii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 43, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 44, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 45;Attorney Docket No: 134524-5009- WO(ix) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 49, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 50, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 51;(x) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 55, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 56, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 57;(xi) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 61, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 62, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 63;(xii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 67, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 68, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 69;(xiii) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 73, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 74, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 75;(xiv) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 79, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 80, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 81;(xv) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 85, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 86, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 87;(xvi) a LCDR1 comprising an amino acid sequence of SEQ ID NO: 91, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 92, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 93; and(xvi) HCDR1 comprising an amino acid sequence of SEQ ID NO: 94, HCDR2 comprising an amino acid sequence of SEQ ID NO: 95, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 96; andb) a VH selected from the group consisting of:(i) HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, HCDR2 comprising an amino acid sequence of SEQ ID NO: 5, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 6;(ii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 10, HCDR2 comprising an amino acid sequence of SEQ ID NO: 11, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 12;Attorney Docket No: 134524-5009- WO(iii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 16, HCDR2 comprising an amino acid sequence of SEQ ID NO: 17, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 18;(iv) HCDR1 comprising an amino acid sequence of SEQ ID NO: 22, HCDR2 comprising an amino acid sequence of SEQ ID NO: 23, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 24;(v) HCDR1 comprising an amino acid sequence of SEQ ID NO: 28, HCDR2 comprising an amino acid sequence of SEQ ID NO: 29, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 30;(vi) HCDR1 comprising an amino acid sequence of SEQ ID NO: 34, HCDR2 comprising an amino acid sequence of SEQ ID NO: 35, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 36;(vii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 40, HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 42;(viii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 46, HCDR2 comprising an amino acid sequence of SEQ ID NO: 47, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 48;(ix) HCDR1 comprising an amino acid sequence of SEQ ID NO: 52, HCDR2 comprising an amino acid sequence of SEQ ID NO: 53, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 54;(x) HCDR1 comprising an amino acid sequence of SEQ ID NO: 58, HCDR2 comprising an amino acid sequence of SEQ ID NO: 59, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 60;(xi) HCDR1 comprising an amino acid sequence of SEQ ID NO: 64, HCDR2 comprising an amino acid sequence of SEQ ID NO: 65, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 66;(xii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 70, HCDR2 comprising an amino acid sequence of SEQ ID NO: 71, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 72;(xiii) HCDR1 comprising an amino acid sequence of SEQ ID NO: 76, HCDR2 comprising an amino acid sequence of SEQ ID NO: 77, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 78;Attorney Docket No: 134524-5009- WO(xiv) HCDR1 comprising an amino acid sequence of SEQ ID NO: 82, HCDR2 comprising an amino acid sequence of SEQ ID NO: 83, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 84;(xv) HCDR1 comprising an amino acid sequence of SEQ ID NO: 88, HCDR2 comprising an amino acid sequence of SEQ ID NO: 89, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 90.

[0126] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 1, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 2, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 3; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, HCDR2 comprising an amino acid sequence of SEQ ID NO: 5, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 6.

[0127] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 1, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 2, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 3; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO: 4, HCDR2 comprising an amino acid sequence of SEQ ID NO: 5, a HCDR3 comprising an amino acid sequence of SEQ ID NO: 6.

[0128] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 7, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 9; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:10, HCDR2 comprising an amino acid sequence of SEQ ID NO: 11, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 12.

[0129] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 7, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 8, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 9; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:10, HCDR2 comprising an amino acid sequence of SEQ ID NO: 11, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 12.

[0130] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 13, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 15; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:16, HCDR2 comprising an amino acid sequence of SEQ ID NO: 17, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 18.

[0131] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 13, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 15; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:16, HCDR2 comprising an amino acid sequence of SEQ ID NO: 17, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 18.

[0132] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 19, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 20, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 21; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:22, HCDR2 comprising an amino acid sequence of SEQ ID NO: 23, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 24.

[0133] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 19, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 20, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 21; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:22, HCDR2 comprising an amino acid sequence of SEQ ID NO: 23, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 24.

[0134] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 25, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 26, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:28, HCDR2 comprising an amino acid sequence of SEQ ID NO: 29, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 30.

[0135] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 25, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 26, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 27; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:28, HCDR2 comprising an amino acid sequence of SEQ ID NO: 29, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 30.

[0136] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 31, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 32, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 33; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:34, HCDR2 comprising an amino acid sequence of SEQ ID NO: 35, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 36.

[0137] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 31, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 32, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 33; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:34, HCDR2 comprising an amino acid sequence of SEQ ID NO: 35, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 36.

[0138] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 37, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 38, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 39; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:40, HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 42.

[0139] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 37, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 38, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 39; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:40, HCDR2 comprising an amino acid sequence of SEQ ID NO: 41, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 42.

[0140] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 43, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 44, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 45; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:46, HCDR2 comprising an amino acid sequence of SEQ ID NO: 47, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 48.

[0141] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 43, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 44, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 45; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:46, HCDR2 comprising an amino acid sequence of SEQ ID NO: 47, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 48.

[0142] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 49, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 50, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 51; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:52, HCDR2 comprising an amino acid sequence of SEQ ID NO: 53, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 54.

[0143] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 49, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 50, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 51; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:52, HCDR2 comprising an amino acid sequence of SEQ ID NO: 53, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 54.

[0144] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 55, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 56, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 57; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:58, HCDR2 comprising an amino acid sequence of SEQ ID NO: 59, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 60.

[0145] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 55, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 56, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 57; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:58, HCDR2 comprising an amino acid sequence of SEQ ID NO: 59, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 60.

[0146] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 61, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 62, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 63; andb) a VH comprising a HCDR1: HCDR1 comprising an amino acid sequence of SEQ ID NO: 64, HCDR2 comprising an amino acid sequence of SEQ ID NO: 65, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 66.

[0147] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 61, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 62, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 63; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:64, HCDR2 comprising an amino acid sequence of SEQ ID NO: 65, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 66.

[0148] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 67, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 68, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 69; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:70, HCDR2 comprising an amino acid sequence of SEQ ID NO: 71, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 72.

[0149] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 67, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 68, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 69; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:70, HCDR2 comprising an amino acid sequence of SEQ ID NO: 71, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 72.

[0150] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 73, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 74, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 75; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:76, HCDR2 comprising an amino acid sequence of SEQ ID NO: 77, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 78.

[0151] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 73, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 74, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 75; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:76, HCDR2 comprising an amino acid sequence of SEQ ID NO: 77, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 78.

[0152] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 79, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 80, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 81; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:82, HCDR2 comprising an amino acid sequence of SEQ ID NO: 83, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 84.

[0153] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 79, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 80, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 81; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:82, HCDR2 comprising an amino acid sequence of SEQ ID NO: 83, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 84.

[0154] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 85, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 86, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 87; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:88, HCDR2 comprising an amino acid sequence of SEQ ID NO: 88, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 90.

[0155] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 85, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 86, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 87; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:88, HCDR2 comprising an amino acid sequence of SEQ ID NO: 88, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 90.

[0156] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, comprising:a) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 91, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 92, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 93; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:94, HCDR2 comprising an amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 96.

[0157] In some embodiments, the present disclosure provides an anti-IL-13 antibody, or antigen-binding fragment thereof, consisting of:Attorney Docket No: 134524-5009- WOa) a VL comprising a LCDR1 comprising an amino acid sequence of SEQ ID NO: 91, a LCDR2 comprising an amino acid sequence of SEQ ID NO: 92, and a LCDR3 comprising an amino acid sequence of SEQ ID NO: 93; andb) a VH comprising a HCDR1 comprising an amino acid sequence of SEQ ID NO:94, HCDR2 comprising an amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising an amino acid sequence of SEQ ID NO: 96.

[0158] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, comprises:a) a VL that is humanized, contains human framework regions, or a combination thereof; and / orb) a VH that is humanized, contains human framework regions, or a combination thereof.

[0159] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, and 127; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, and 128.

[0160] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof consists of:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from theAttorney Docket No: 134524-5009- WOgroup consisting of: SEQ ID NOs: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, and 127; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, and 128.

[0161] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, and 127; andb) a VH consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, and 128.

[0162] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof consists of:a) a VL consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, and 127; andb) a VH consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected fromAttorney Docket No: 134524-5009- WOthe group consisting of: SEQ ID NOs: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, and 128.

[0163] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence selected from the group consisting of:SEQ ID NOs: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, and 127; andb) a VH comprising an amino acid sequence selected from the group consisting of:SEQ ID NOs: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, and 128.

[0164] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence selected from the group consisting of:SEQ ID NOs: 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, and 127; andb) a VH consisting of an amino acid sequence selected from the group consisting of:SEQ ID NOs: 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, and 128.

[0165] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 97; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 98.

[0166] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 97; andb) a VH comprising an amino acid sequence of SEQ ID NO: 98.Attorney Docket No: 134524-5009- WO

[0167] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 97; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 98.

[0168] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 99; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 100.

[0169] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 99; andb) a VH comprising an amino acid sequence of SEQ ID NO: 100.

[0170] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 99; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 100.

[0171] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 101; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 102.

[0172] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 101; andb) a VH comprising an amino acid sequence of SEQ ID NO: 102.

[0173] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 101; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 102.

[0174] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 103; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 104.

[0175] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 103; andb) a VH comprising an amino acid sequence of SEQ ID NO: 104.

[0176] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 103; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 104.

[0177] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:Attorney Docket No: 134524-5009- WOa) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 105; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 106.

[0178] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 105; andb) a VH comprising an amino acid sequence of SEQ ID NO: 106.

[0179] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 105; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 106.

[0180] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 107; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 108.

[0181] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 107; andb) a VH comprising an amino acid sequence of SEQ ID NO: 108.Attorney Docket No: 134524-5009- WO

[0182] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 107; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 108.

[0183] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 109; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 110.

[0184] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 109; andb) a VH comprising an amino acid sequence of SEQ ID NO: 110.

[0185] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 109; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 110.

[0186] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 111; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 112.

[0187] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 111; andb) a VH comprising an amino acid sequence of SEQ ID NO: 112.

[0188] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 111; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 112.

[0189] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 113; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 114.

[0190] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 113; andb) a VH comprising an amino acid sequence of SEQ ID NO: 114.

[0191] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 113; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 114.

[0192] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:Attorney Docket No: 134524-5009- WOa) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 115; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 116.

[0193] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 115; andb) a VH comprising an amino acid sequence of SEQ ID NO: 116.

[0194] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 115; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 116.

[0195] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 117; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 118.

[0196] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 117; andb) a VH comprising an amino acid sequence of SEQ ID NO: 118.Attorney Docket No: 134524-5009- WO

[0197] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 117; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 118.

[0198] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 119; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 120.

[0199] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 119; andb) a VH comprising an amino acid sequence of SEQ ID NO: 120.

[0200] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 119; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 120.

[0201] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 121; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 122.

[0202] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 121; andb) a VH comprising an amino acid sequence of SEQ ID NO: 122.

[0203] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 121; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 122.

[0204] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 123; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 124.

[0205] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 123; andb) a VH comprising an amino acid sequence of SEQ ID NO: 124.

[0206] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 123; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 124.

[0207] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:Attorney Docket No: 134524-5009- WOa) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 125; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 126.

[0208] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 125; andb) a VH comprising an amino acid sequence of SEQ ID NO: 126.

[0209] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 125; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 126.

[0210] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 127; andb) a VH comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence of SEQ ID NO: 128.

[0211] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL comprising an amino acid sequence of SEQ ID NO: 127; andb) a VH comprising an amino acid sequence of SEQ ID NO: 128.Attorney Docket No: 134524-5009- WO

[0212] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a VL consisting of an amino acid sequence of SEQ ID NO: 127; andb) a VH consisting of an amino acid sequence of SEQ ID NO: 128.

[0213] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a light chain (LC) comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; andb) a heavy chain (HC) comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0214] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof consists of:a) a light chain (LC) comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; andb) a heavy chain (HC) comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 130, 132, 134, 136, 138, 140, 142, 144,Attorney Docket No: 134524-5009- WO146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0215] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a light chain (LC) consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; andb) a heavy chain (HC) consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0216] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof consists of:a) a light chain (LC) consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; andb) a heavy chain (HC) consisting of an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to an amino acid sequence selected from the group consisting of: SEQ ID NOs: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187,Attorney Docket No: 134524-5009- WO188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0217] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a light chain (LC) comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; andb) a heavy chain (HC) comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0218] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof comprises:a) a light chain (LC) consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, or 159; andb) a heavy chain (HC) consisting of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, or 211.

[0219] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 129; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 130.

[0220] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 129; andAttorney Docket No: 134524-5009- WOb) a HC comprising an amino acid sequence of SEQ ID NO: 130.

[0221] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 131; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 132.

[0222] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 131; andb) a HC comprising an amino acid sequence of SEQ ID NO: 132.

[0223] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 133; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 134.

[0224] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 133; andb) a HC comprising an amino acid sequence of SEQ ID NO: 134.

[0225] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 135; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 136.

[0226] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 135; andb) a HC comprising an amino acid sequence of SEQ ID NO: 136.

[0227] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 137; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 138.

[0228] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 137; andb) a HC comprising an amino acid sequence of SEQ ID NO: 138.

[0229] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 139; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 140.

[0230] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 139; andb) a HC comprising an amino acid sequence of SEQ ID NO: 140.

[0231] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 142.

[0232] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 142.

[0233] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 143; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 144.

[0234] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 143; andb) a HC comprising an amino acid sequence of SEQ ID NO: 144.

[0235] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 145; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 146.

[0236] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 145; andAttorney Docket No: 134524-5009- WOb) a HC comprising an amino acid sequence of SEQ ID NO: 146.

[0237] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 148.

[0238] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 148.

[0239] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 149; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 150.

[0240] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 149; andb) a HC comprising an amino acid sequence of SEQ ID NO: 150.

[0241] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 151; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 152.

[0242] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 151; andb) a HC comprising an amino acid sequence of SEQ ID NO: 152.

[0243] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 154.

[0244] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 154.

[0245] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 155; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 156.

[0246] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 155; andb) a HC comprising an amino acid sequence of SEQ ID NO: 156.

[0247] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 157; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 158.

[0248] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 157; andb) a HC comprising an amino acid sequence of SEQ ID NO: 158.

[0249] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 159; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 160.

[0250] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 159; andb) a HC comprising an amino acid sequence of SEQ ID NO: 160.

[0251] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 182.

[0252] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andAttorney Docket No: 134524-5009- WOb) a HC comprising an amino acid sequence of SEQ ID NO: 182.

[0253] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 183.

[0254] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 183.

[0255] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 184.

[0256] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 184.

[0257] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 183.

[0258] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 183.

[0259] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 186.

[0260] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 186.

[0261] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 187.

[0262] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 187.

[0263] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 188.

[0264] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 188.

[0265] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 189.

[0266] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 189.

[0267] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 190.

[0268] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andAttorney Docket No: 134524-5009- WOb) a HC comprising an amino acid sequence of SEQ ID NO: 190.

[0269] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 191.

[0270] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 191.

[0271] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 192.

[0272] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 192.

[0273] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 193.

[0274] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 193.

[0275] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 194.

[0276] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 194.

[0277] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 195.

[0278] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 195.

[0279] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 196.

[0280] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 196.

[0281] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 197.

[0282] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 197.

[0283] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 198.

[0284] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andAttorney Docket No: 134524-5009- WOb) a HC comprising an amino acid sequence of SEQ ID NO: 198.

[0285] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 199.

[0286] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 199.

[0287] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 200.

[0288] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 200.

[0289] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 201.

[0290] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 201.

[0291] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 202.

[0292] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 202.

[0293] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 203.

[0294] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 203.

[0295] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 204.

[0296] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 204.

[0297] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 205.

[0298] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 205.

[0299] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 206.

[0300] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andAttorney Docket No: 134524-5009- WOb) a HC comprising an amino acid sequence of SEQ ID NO: 206.

[0301] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 207.

[0302] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 207.

[0303] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 208.

[0304] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 208.

[0305] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least aboutAttorney Docket No: 134524-5009- WO95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 209.

[0306] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 153; andb) a HC comprising an amino acid sequence of SEQ ID NO: 209.

[0307] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 210.

[0308] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 147; andb) a HC comprising an amino acid sequence of SEQ ID NO: 210.

[0309] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence having at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% sequence identity to sequence of SEQ ID NO: 211.

[0310] In some embodiments, an antibody of the present disclosure comprises:a) a LC comprising an amino acid sequence of SEQ ID NO: 141; andb) a HC comprising an amino acid sequence of SEQ ID NO: 211.

[0311] In some embodiments, an antibody HC is translated in a cell with a signal sequence to target the HC for secretion. In some embodiments, a HC comprises an N-terminal signal sequence that is cleaved prior to secretion.Attorney Docket No: 134524-5009- WO

[0312] In some embodiments, an antibody LC is translated in a cell with a signal sequence to target the LC for secretion. In some embodiments, a LC comprises an N-terminal signal sequence that is cleaved prior to secretion.

[0313] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3) provided in Table 1 or Table 2. In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3) provided in Table 1 or Table 2. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3), provided in Table 1 or Table 2, wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13. For example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 1 or Table 2 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abl, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). The anti-IL-13 antibody or antigen binding fragment thereof that binds IL-13 may also comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 1 or Table 2 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abl, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). For another example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 1 or Table 2 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abl, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP), wherein the anti-IL-13 antibody or antibody fragment thereof binds IL-13.Table 1: CDR Sequences of Anti-IL-13 Antibody Variable Heavy Chains According to Kabat NumberingAnti-IL-13 Ab HCDR1 HCDR2 HCDR3AYSVN MIWGDGKIVYNSALKS DGYYPYAMDNAbA(SEQ ID NO: 4) (SEQ ID NO: 5) (SEQ ID NO: 6) AYSVN MIWGDGKIVYNSALKS DGYYPYAMDNAbB(SEQ ID NO: 10) (SEQ ID NO: 11) (SEQ ID NO: 12) AYSVN MIWGDGKIVYNSALKS DGYYPYAMDYAbC(SEQ ID NO: 16) (SEQ ID NO: 17) (SEQ ID NO: 18)Attorney Docket No: 134524-5009- WOAYSVN MIWGDGKVVYNSALKS DGYFPYAMDNAbD(SEQ ID NO: 22) (SEQ ID NO: 23) (SEQ ID NO: 24) AbE AYSVN MIWGDGKIVYNSALKS DGYFPYAMDN (SEQ ID NO: 28) (SEQ ID NO: 29) (SEQ ID NO: 30) AbF RYSVN MIWGDAKIVYNSALKS DGYFPYAMDN (SEQ ID NO: 34) (SEQ ID NO: 35) (SEQ ID NO: 36) AbG AYSVN MIWGDGKIVYNSALKS DGYFPYAMDN (SEQ ID NO: 40) (SEQ ID NO: 41) (SEQ ID NO: 42) AbH RYSVN MIWGDGKIVYNSALKS DGYYPYAMDN (SEQ ID NO: 46) (SEQ ID NO: 47) (SEQ ID NO: 48) Abl RYSVN MIWGDGKIVYNSALKS DGFYPYAMDN (SEQ ID NO: 52) (SEQ ID NO: 53) (SEQ ID NO: 54) AbJ AYSVN MIWGDRKKVYNSALKS DGYFPYAMDL (SEQ ID NO: 58) (SEQ ID NO: 59) (SEQ ID NO: 60) AbK RYSVN MIWGDGKIVYNSALKS DGYYPYAMDN (SEQ ID NO: 64) (SEQ ID NO: 65) (SEQ ID NO: 66) AbL RYSVN MIWGDGKIVYNSALKS DGYYPYAMDN (SEQ ID NO: 70) (SEQ ID NO: 71) (SEQ ID NO: 72) AbM AYSVN MIWGDGKIVYNSALKS DGYFPYAMDN (SEQ ID NO: 76) (SEQ ID NO: 77) (SEQ ID NO: 78) AbN AYSVN MIWGDGKIVYNSALKS DGYYPYAMDN (SEQ ID NO: 82) (SEQ ID NO: 83) (SEQ ID NO: 84) AbO AYSVN MIWGDGKIVYNSALKS DGYFPYAMDV (SEQ ID NO: 88) (SEQ ID NO: 88) (SEQ ID NO: 90) AbP AYSVN MIWGDGKVVYNSALKS DGYFPYAMDHAttorney Docket No: 134524-5009- WO(SEQ ID NO: 94) (SEQ ID NO: 95) (SEQ ID NO: 96)Table 2: CDR Sequences of Anti-IL-13 Antibody Variable Heavy Chains According to Chothia NumberingAnti-IL-13 Ab HCDR1 HCDR2 HCDR3GFSLSAY WGDGK DGYYPYAMDNAbA(SEQ ID NO: 251) (SEQ ID NO: 252) (SEQ ID NO: 6) GASLSAY WGDGK DGYYPYAMDNAbB(SEQ ID NO: 253) (SEQ ID NO: 254) (SEQ ID NO: 12) GFSLSAY WGDGK DGYYPYAMDYAbC(SEQ ID NO: 255) (SEQ ID NO: 256) (SEQ ID NO: 18) GSSLSAY WGDGK DGYFPYAMDNAbD(SEQ ID NO: 257) (SEQ ID NO: 258) (SEQ ID NO: 24) AbE GASLSAY WGDGK DGYFPYAMDN (SEQ ID NO: 259) (SEQ ID NO: 260) (SEQ ID NO: 30) AbF GASLSRY WGDAK DGYFPYAMDN (SEQ ID NO: 261) (SEQ ID NO: 262) (SEQ ID NO: 36) AbG GASLSAY WGDGK DGYFPYAMDN (SEQ ID NO: 263) (SEQ ID NO: 264) (SEQ ID NO: 42) AbH GASLSRY WGDGK DGYYPYAMDN (SEQ ID NO: 265) (SEQ ID NO: 266) (SEQ ID NO: 48) Abl GASLSRY WGDGK DGFYPYAMDN (SEQ ID NO: 267) (SEQ ID NO: 268) (SEQ ID NO: 54) AbJ GASLSAY WGDRK DGYFPYAMDL (SEQ ID NO: 269) (SEQ ID NO: 270) (SEQ ID NO: 60)Attorney Docket No: 134524-5009- WOAbK GSSLSRY WGDGK DGYYPYAMDN (SEQ ID NO: 271) (SEQ ID NO: 272) (SEQ ID NO: 66) AbL GFSLSRY WGDGK DGYYPYAMDN (SEQ ID NO: 273) (SEQ ID NO: 274) (SEQ ID NO: 72) AbM GASLSAY WGDGK DGYFPYAMDN (SEQ ID NO: 275) (SEQ ID NO: 276) (SEQ ID NO: 78) AbN GASLSAY WGDGK DGYYPYAMDN (SEQ ID NO: 277) (SEQ ID NO: 278) (SEQ ID NO: 84) AbO GYSLSAY WGDGK DGYFPYAMDV (SEQ ID NO: 279) (SEQ ID NO: 280) (SEQ ID NO: 90) AbP GASLSAY WGDGK DGYFPYAMDH (SEQ ID NO: 281) (SEQ ID NO: 282) (SEQ ID NO: 96)

[0314] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) as provided in Table 3 or Table 4. In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) as provided in Table 3 or Table 4. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13, as provided in Table 3 or Table 4. For example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 3 or Table 4 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abl, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). The antibody or antigen binding fragment thereof that binds IL-13 may also comprise a set of CDRs corresponding to those CDRs in one or more of the antibodies provided in Table 3 or Table 4 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abl, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP). For another example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of CDRs corresponding to those CDRs in one or more of the anti-IL-13 antibodies provided in Table 3 or Table 4 (e.g., the CDRs of AbA, AbB,Attorney Docket No: 134524-5009- WOAbC, AbD, AbE, AbF, AbG, AbH, Abl, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP), wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13.Table 3: CDR Sequences of Anti-IL-13 Antibody Variable Light Chains According to Kabat NumberingAnti-IL-13 Ab LCDR1 LCDR2 LCDR3RASKSVDSYGRSYMH LASNLES QQNNEDPRTAbA(SEQ ID NO: 1) (SEQ ID NO: 2) (SEQ ID NO: 3) RASKSVDYYGHSYMH LASNLES QQNNEDPRTAbB(SEQ ID NO: 7) (SEQ ID NO: 8) (SEQ ID NO: 9) RASKSVDYYGNSYMH LASNLES QQNNEDPRTAbC(SEQ ID NO: 13) (SEQ ID NO: 14) (SEQ ID NO: 15) RASKSVDSYGNSYMH LASNLES QQNNEDPRTAbD(SEQ ID NO: 19) (SEQ ID NO: 20) (SEQ ID NO: 21) AbE RASKSVDSYGHSYMH WASNLES QQNNEDPRT(SEQ ID NO: 25) (SEQ ID NO: 26) (SEQ ID NO: 27) AbF RASESVDSYGNSYMH LASNLES QQNNEDPRT(SEQ ID NO: 31) (SEQ ID NO: 32) (SEQ ID NO: 33) AbG RASKSVDSYGNSYMH LASNLES QQNNEDPRT(SEQ ID NO: 37) (SEQ ID NO: 38) (SEQ ID NO: 39) AbH RASKSVDSYGNSYMH RASNLES QQNNEDPRT(SEQ ID NO: 43) (SEQ ID NO: 44) (SEQ ID NO: 45) Abl RASKSVDSYGNSYMH LASNLES QQNNEDPRT(SEQ ID NO: 49) (SEQ ID NO: 50) (SEQ ID NO: 51) AbJ RASKSVDSYGHSYMH WASNLES QQNNEDPRT(SEQ ID NO: 55) (SEQ ID NO: 56) (SEQ ID NO: 57) AbK RASQSVDSYGNSYMH LASNLES QQNNEDPRTAttorney Docket No: 134524-5009- WO(SEQ ID NO: 61) (SEQ ID NO: 62) (SEQ ID NO: 63) AbL RASKSVDSYGRSYMH LASNLES QQNNEDPRT(SEQ ID NO: 67) (SEQ ID NO: 68) (SEQ ID NO: 69) AbM RASKSVDYYGRSYMH LASNLES QQNNEDPRT(SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75) AbN RASESVDYYGHSYMH LASNLES QQNNEDPRT(SEQ ID NO: 79) (SEQ ID NO: 80) (SEQ ID NO: 81) AbO RASKSVDYYGHSYMH LASNLES QQNNEDPRT(SEQ ID NO: 85) (SEQ ID NO: 86) (SEQ ID NO: 87) AbP RASKSVDSYGNSYMH WASNLES QQNNEDPRT(SEQ ID NO: 91) (SEQ ID NO: 92) (SEQ ID NO: 93)Table 4: CDR Sequences of Anti-IL-13 Antibody Variable Light Chains According to Chothia NumberingAnti-IL-13 Ab LCDR1 LCDR2 LCDR3RASKSVDSYGRSYMH LASNLES QQNNEDPRTAbA(SEQ ID NO: 1) (SEQ ID NO: 2) (SEQ ID NO: 3) RASKSVDYYGHSYMH LASNLES QQNNEDPRTAbB(SEQ ID NO: 7) (SEQ ID NO: 8) (SEQ ID NO: 9) RASKSVDYYGNSYMH LASNLES QQNNEDPRTAbC(SEQ ID NO: 13) (SEQ ID NO: 14) (SEQ ID NO: 15) RASKSVDSYGNSYMH LASNLES QQNNEDPRTAbD(SEQ ID NO: 19) (SEQ ID NO: 20) (SEQ ID NO: 21) AbE RASKSVDSYGHSYMH WASNLES QQNNEDPRT(SEQ ID NO: 25) (SEQ ID NO: 26) (SEQ ID NO: 27)Attorney Docket No: 134524-5009- WOAbF RASESVDSYGNSYMH LASNLES QQNNEDPRT(SEQ ID NO: 31) (SEQ ID NO: 32) (SEQ ID NO: 33) AbG RASKSVDSYGNSYMH LASNLES QQNNEDPRT(SEQ ID NO: 37) (SEQ ID NO: 38) (SEQ ID NO: 39) AbH RASKSVDSYGNSYMH RASNLES QQNNEDPRT(SEQ ID NO: 43) (SEQ ID NO: 44) (SEQ ID NO: 45)AbI RASKSVDSYGNSYMH LASNLES QQNNEDPRT(SEQ ID NO: 49) (SEQ ID NO: 50) (SEQ ID NO: 51) AbJ RASKSVDSYGHSYMH WASNLES QQNNEDPRT(SEQ ID NO: 55) (SEQ ID NO: 56) (SEQ ID NO: 57) AbK RASQSVDSYGNSYMH LASNLES QQNNEDPRT(SEQ ID NO: 61) (SEQ ID NO: 62) (SEQ ID NO: 63) AbL RASKSVDSYGRSYMH LASNLES QQNNEDPRT(SEQ ID NO: 67) (SEQ ID NO: 68) (SEQ ID NO: 69) AbM RASKSVDYYGRSYMH LASNLES QQNNEDPRT(SEQ ID NO: 73) (SEQ ID NO: 74) (SEQ ID NO: 75) AbN RASESVDYYGHSYMH LASNLES QQNNEDPRT(SEQ ID NO: 79) (SEQ ID NO: 80) (SEQ ID NO: 81) AbO RASKSVDYYGHSYMH LASNLES QQNNEDPRT(SEQ ID NO: 85) (SEQ ID NO: 86) (SEQ ID NO: 87) AbP RASKSVDSYGNSYMH WASNLES QQNNEDPRT(SEQ ID NO: 91) (SEQ ID NO: 92) (SEQ ID NO: 93)

[0315] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a heavy chain variable domain (VH) and light chain variable domain (VL) in Table 5. In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 compriseAttorney Docket No: 134524-5009- WOVH and VL sequences provided in Table 5. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3) provided in Table 1 or Table 2, a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) provided in Table 3 or Table 4, and VH and VL sequences are at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the sequences provided in provided in Table 5, wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13. For example, the anti-IL-13 antibody or antigen binding fragment thereof may comprise a set of VH and VL sequences provided in Table 5 (e.g., the CDRs of AbA, AbB, AbC, AbD, AbE, AbF, AbG, AbH, Abl, AbJ, AbK, AbL, AbM, AbN, AbO, or AbP).Table 5: Heavy Chain Variable Domain (VH) and Light Chain Variable Domain (VL) Sequences of Illustrative Antibodies of the Present DisclosureAnti-IL-13 Ab VH VL QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR FSLSAYSVNWIRQPPGKALEWLAMI ASKSVDSYGRSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbAVVLTMTN M DPVDTATYYCAG DGYY SGTDFTLTISSLQAEDVAVYYCQQ PYAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 98) NO: 97) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSAYSVNWIRQPPGKALEWLAMI ASKSVDYYGHSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbBVVLTMTNMDPVDTATYYCAGDGYY SGTDFTLTISSLQAEDVAVYYCQQ PYAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 100) NO: 99) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR FSLSAYSVNWIRQPPGKALEWLAMI ASKSVDYYGNSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbCVVLTMTN M DPVDTATYYCAG DGYY SGTDFTLTISSLQAEDVAVYYCQQ PYAMDYWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 102) NO: 101) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR SSLSAYSVNWIRQPPGKALEWLAMI ASKSVDSYGNSYMHWYQQKPGQ WGDGKVVYNSALKSRLTISKDTSKN PPKLLIYLASNLESGVPDRFSGSGAbDQVVLTMTNMDPVDTATYYCAGDGY SGTDFTLTISSLQAEDVAVYYCQQ FPYAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 104) NO: 103) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSAYSVNWIRQPPGKALEWLAMI ASKSVDSYGHSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYWASNLESGVPDRFSGSGAbEVVLTMTNMDPVDTATYYCAGDGYFP SGTDFTLTISSLQAEDVAVYYCQQ YAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ IDNO: 106) NO: 105)Attorney Docket No: 134524-5009- WOQVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSRYSVNWIRQPPGKALEWLAMI ASESVDSYGNSYMHWYQQKPGQ WGDAKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbFVVLTMTNMDPVDTATYYCAGDGYFP SGTDFTLTISSLQAEDVAVYYCQQ YAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 108) NO: 107) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSAYSVNWIRQPPGKALEWLAMI ASKSVDSYGNSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbG VVLTMTNMDPVDTATYYCAGDGYFP SGTDFTLTISSLQAEDVAVYYCQQ YAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 110) NO: 109) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSRYSVNWIRQPPGKALEWLAMI ASKSVDSYGNSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYRASNLESGVPDRFSGSGAbHVVLTMTN M DPVDTATYYCAG DGYY SGTDFTLTISSLQAEDVAVYYCQQ PYAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 112) NO: 111) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSRYSVNWIRQPPGKALEWLAMI ASKSVDSYGNSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAblVVLTMTN M D P VDTATYYCAG DG F YP SGTDFTLTISSLQAEDVAVYYCQQ YAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 114) NO: 113) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSAYSVNWIRQPPGKALEWLAMI ASKSVDSYGNSYMHWYQQKPGQ WGDRKKVYNSALKSRLTISKDTSKNAbJ PPKLLIYWASNLESGVPDRFSGSG QVVLTMTNMDPVDTATYYCAGDGY SGTDFTLTISSLQAEDVAVYYCQQ FPYAMDLWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 116) NO: 115) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR SSLSRYSVNWIRQPPGKALEWLAMI ASQSVDSYGNSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQAbK PPKLLIYLASNLESGVPDRFSGSG VVLTMTN M DPVDTATYYCAG DGYY SGTDFTLTISSLQAEDVAVYYCQQ PYAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 118) NO: 117) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR FSLSRYSVNWIRQPPGKALEWLAMI ASKSVDSYGRSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbLVVLTMTN M DPVDTATYYCAG DGYY SGTDFTLTISSLQAEDVAVYYCQQ PYAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 120) NO: 119) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSAYSVNWIRQPPGKALEWLAMI ASKSVDYYGRSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbMVVLTMTNMDPVDTATYYCAGDGYFP SGTDFTLTISSLQAEDVAVYYCQQ YAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 122) NO: 121) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCRAbNASLSAYSVNWIRQPPGKALEWLAMI ASESVDYYGHSYMHWYQQKPGQAttorney Docket No: 134524-5009- WOWGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSG VVLTMTN M DPVDTATYYCAG DGYY SGTDFTLTISSLQAEDVAVYYCQQ PYAMDNWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 124) NO: 123) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR YSLSAYSVNWIRQPPGKALEWLAMI ASKSVDYYGHSYMHWYQQKPGQ WGDGKIVYNSALKSRLTISKDTSKNQ PPKLLIYLASNLESGVPDRFSGSGAbOVVLTMTNMDPVDTATYYCAGDGYFP SGTDFTLTISSLQAEDVAVYYCQQ YAMDVWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ ID NO: 126) NO: 125) QVTLRESGPALVKPTQTLTLTCTVSG DI VMTQSPDSLSVSLGERATI NCR ASLSAYSVNWI RQPPGKALEWLAMI ASKSVDSYGNSYMHWYQQKPGQ WGDGKVVYNSALKSRLTISKDTSKN PPKLLIYWASNLESGVPDRFSGSGAbPQVVLTMTNMDPVDTATYYCAGDGY SGTDFTLTISSLQAEDVAVYYCQQ FPYAMDHWGQGSLVTVSS (SEQ ID NNEDPRTFGGGTKVEIK (SEQ IDNO: 128) NO: 127)

[0316] In some embodiments, the anti-IL-13 antibodies or antigen binding fragments thereof comprise a heavy chain (HC) and light chain (LC) in Table 6. In some embodiments, the antibodies or antigen binding fragments thereof that bind IL-13 comprise HC and LC sequences provided in Table 6. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises a VH having a set of CDRs (HCDR1, HCDR2, and HCDR3) provided in Table 1 or Table 2, a VL having a set of CDRs (LCDR1, LCDR2, and LCDR3) provided in Table 3 or Table 4, and LC and HC sequences are at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the sequences provided in provided in Table 6, wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL- 13. In some embodiments, the anti-IL-13 antibody or antigen binding fragment thereof comprises heavy chain variable domain (VH) and light chain variable domain (VL) provided in Table 5, and LC and HC sequences are at least about 95%, or at least about 96%, or at least about 97%, or at least about 98%, or at least about 99% identical to the sequences provided in provided in Table 6, wherein the anti-IL-13 antibody or antigen binding fragment thereof binds IL-13.Table 6: Heavy Chain (HC) and Light Chain (LC) Sequences of Illustrative Antibodies of the Present DisclosureAnti-IL-13 ChainSequenceAbAbA LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 129)Attorney Docket No: 134524-5009- WOAbB LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGHSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 131) AbC LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 133) AbD LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 135) AbE LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 137) AbF LC DIVMTQSPDSLSVSLGERATINCRASESVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 139) AbG LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbH LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYRASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 143) Abl LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 145) AbJ LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbK LC DIVMTQSPDSLSVSLGERATINCRASQSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 149)Attorney Docket No: 134524-5009- WOAbL LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 151) AbM LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbN LC DIVMTQSPDSLSVSLGERATINCRASESVDYYGHSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 155) AbO LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGHSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 157) AbP LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 159) AbQ LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbR LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbS LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbT LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbU LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147)Attorney Docket No: 134524-5009- WOAbV LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbW LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbX LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbY LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbZ LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbAA LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbAB LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbAC LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbAD LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbAE LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141)Attorney Docket No: 134524-5009- WOAbAF LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbAG LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbAH LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbAI LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbAJ LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbAK LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbAL LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbAM LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASWCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbAN LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbAO LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153)Attorney Docket No: 134524-5009- WOAbAP LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbAQ LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbAR LC DIVMTQSPDSLSVSLGERATINCRASKSVDYYGRSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 153) AbAS LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGHSYMHWYQQKPG QPPKLLIYWASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 147) AbAT LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSYMHWYQQKPG QPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 141) AbA HC QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 130) AbB HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 132) AbC HC QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYYPYAMDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCAttorney Docket No: 134524-5009- WOPAPELLGGPSVFLFPPKPKDTLYITREPEVTCWVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 134) AbD HC QVTLRESGPALVKPTQTLTLTCTVSGSSLSAYSVNWIRQPPGKALE WLAMIWGDGKVVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTAT YYCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 136) AbE HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 138) AbF HC QVTLRESGPALVKPTQTLTLTCTVSGASLSRYSVNWIRQPPGKALE WLAMIWGDAKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 140) AbG HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 142) AbH HC QVTLRESGPALVKPTQTLTLTCTVSGASLSRYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCAttorney Docket No: 134524-5009- WOPAPELLGGPSVFLFPPKPKDTLYITREPEVTCWVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 144) Abl HC QVTLRESGPALVKPTQTLTLTCTVSGASLSRYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGFYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 146) AbJ HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLYITREPEVTCWVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 148) AbK HC QVTLRESGPALVKPTQTLTLTCTVSGSSLSRYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 150) AbL HC QVTLRESGPALVKPTQTLTLTCTVSGFSLSRYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 152) AbM HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCAttorney Docket No: 134524-5009- WOPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 154) AbN HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 156) AbO HC QVTLRESGPALVKPTQTLTLTCTVSGYSLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDVWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 158) AbP HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKVVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTAT YYCAGDGYFPYAMDHWGQGSLVTVSSASTKGPSVFPLAPSSKSTS GGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPELLGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 160) AbQ HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGAPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 182) AbR HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPAttorney Docket No: 134524-5009- WOCPAPEAAGAPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 183) AbS HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGAPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 184) AbT HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALAAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 185) AbU HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALAAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 186) AbV HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALAAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 187) AbW HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCAttorney Docket No: 134524-5009- WOPAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALGAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 188) AbX HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 189) AbY HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALGAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 190) AbZ HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 191) AbAA HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 192) AbAB HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCAttorney Docket No: 134524-5009- WOPAPEFEGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 193) AbAC HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 194) AbAD HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 195) AbAE HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 196) AbAF HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALGAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 197) AbAG HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPAttorney Docket No: 134524-5009- WOCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 198) AbAH HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALGAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 199) AbAI HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALAAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 200) AbAJ HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALAAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 201) AbAK HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALAAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 202) AbAL HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCAttorney Docket No: 134524-5009- WOPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 203) AbAM HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 204) AbAN HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGAPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 205) AbAO HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 206) AbAP HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 207) AbAQ HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCAttorney Docket No: 134524-5009- WOPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 208) AbAR HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SWTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRWSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 209) AbAS HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDRKKVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYFPYAMDLWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPP CPAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVWDVSHEDPEVKF NWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYK CKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 210) AbAT HC QVTLRESGPALVKPTQTLTLTCTVSGASLSAYSVNWIRQPPGKALE WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATY YCAGDGYFPYAMDNWGQGSLVTVSSASTKGPSVFPLAPSSKSTSG GTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLS SVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPC PAPEAAGGPSVFLFPPKPKDTLYITREPEVTCVVVDVSHEDPEVKFN WYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCL VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK (SEQ ID NO: 211)

[0317] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof:a) binds to IL-13 with a KDof about 10 pM or less (e.g., as measured by KinExA); b) binds to an epitope in IL-13 (e.g., in a full-length human IL-13);c) competes with a Reference Antibody (e.g., Lebrikizumab) for binding to IL-13; d) reduces binding of IL-13 protein to IL-13R;e) modulates (e.g., reduces, inhibits, neutralizes) against an IL-13-mediated biological activity; orf) a combination thereof.Attorney Docket No: 134524-5009- WO

[0318] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to IL-13 (e.g., human or cynomolgus monkey IL-13) with a KDof 10 pM or less (e.g., as measured by KinExA).

[0319] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to IL-13 with a KDof about 0.01 pM to about 10 pM, about 0.05 pM to about 10 pM, about 0.1 pM to about 10 pM, about 0.15 pM to about 10 pM, about 0.2 pM to about 10 pM, about 0.25 pM to about 10 pM, about 0.3 pM to about 10 pM, about 0.35 pM to about 10 pM, about 0.4 pM to about 10 pM, about 0.45 pM to about 10 pM, about 0.5 pM to about 10 pM, about 0.55 pM to about 10 pM, about 0.6 pM to about 10 pM, about 0.65 pM to about 10 pM, about 0.7 pM to about 10 pM, about 0.75 pM to about 10 pM, about 0.8 pM to about 10 pM, about 0.85 pM to about 10 pM, about 0.9 pM to about 10 pM, about 0.95 pM to about 10 pM, about 1 pM to about 10 pM, about 1.5 pM to about 10 pM, about 2 pM to about 10 pM, about 2.5 pM to about 10 pM, about 3 pM to about 10 pM, about 3.5 pM to about 10 pM, about 4 pM to about 10 pM, about 4.5 pM to about 10 pM, about 5 pM to about 10 pM, about 5.5 pM to about 10 pM, about 6 pM to about 10 pM, about 6.5 pM to about 10 pM, about 7 pM to about 10 pM, about 7.5 pM to about 10 pM, about 8 pM to about 10 pM, about 8.5 pM to about 10 pM, about 9 pM to about 10 pM, about 0.01 pM to about 8 pM, about 0.05 pM to about 8 pM, about 0.1 pM to about 8 pM, about 0.15 pM to about 8 pM, about 0.2 pM to about 8 pM, about 0.25 pM to about 8 pM, about 0.3 pM to about 8 pM, about 0.35 pM to about 8 pM, about 0.4 pM to about 8 pM, about 0.45 pM to about 8 pM, about 0.5 pM to about 8 pM, about 0.55 pM to about 8 pM, about 0.6 pM to about 8 pM, about 0.65 pM to about 8 pM, about 0.7 pM to about 8 pM, about 0.75 pM to about 8 pM, about 0.8 pM to about 8 pM, about 0.85 pM to about 8 pM, about 0.9 pM to about 8 pM, about 0.95 pM to about 8 pM, about 1 pM to about 8 pM, about 1.5 pM to about 8 pM, about 2 pM to about 8 pM, about 2.5 pM to about 8 pM, about 3 pM to about 8 pM, about 3.5 pM to about 8 pM, about 4 pM to about 8 pM, about 4.5 pM to about 8 pM, about 5 pM to about 8 pM, about 5.5 pM to about 8 pM, about 6 pM to about 8 pM, about 6.5 pM to about 8 pM, about 7 pM to about 8 pM, about 7.5 pM to about 8 pM, about 0.01 pM to about 6 pM, about 0.05 pM to about 6 pM, about 0.1 pM to about 6 pM, about 0.15 pM to about 6 pM, about 0.2 pM to about 6 pM, about 0.25 pM to about 6 pM, about 0.3 pM to about 6 pM, about 0.35 pM to about 6 pM, about 0.4 pM to about 6 pM, about 0.45 pM to about 6 pM, about 0.5 pM to about 6 pM, about 0.55 pM to about 6 pM, about 0.6 pM to about 6 pM, about 0.65 pM to about 6 pM, about 0.7 pM to about 6 pM, about 0.75 pM to about 6 pM, about 0.8 pM to about 6 pM, about 0.85 pM to about 6 pM, about 0.9 pM to about 6 pM, about 0.95 pM to about 6 pM, about 1 pM to about 6 pM, about 1.5 pM to about 6 pM, about 2 pM to about 6 pM, about 2.5 pM to about 6 pM, about 3 pM to about 6 pM,Attorney Docket No: 134524-5009- WOabout 3.5 pM to about 6 pM, about 4 pM to about 6 pM, about 4.5 pM to about 6 pM, about 5 pM to about 6 pM, about 5.5 pM to about 6 pM, about 0.01 pM to about 4 pM, about 0.05 pM to about 4 pM, about 0.1 pM to about 4 pM, about 0.15 pM to about 4 pM, about 0.2 pM to about 4 pM, about 0.25 pM to about 4 pM, about 0.3 pM to about 4 pM, about 0.35 pM to about 4 pM, about 0.4 pM to about 4 pM, about 0.45 pM to about 4 pM, about 0.5 pM to about 4 pM, about 0.55 pM to about 4 pM, about 0.6 pM to about 4 pM, about 0.65 pM to about 4 pM, about 0.7 pM to about 4 pM, about 0.75 pM to about 4 pM, about 0.8 pM to about 4 pM, about 0.85 pM to about 4 pM, about 0.9 pM to about 4 pM, about 0.95 pM to about 4 pM, about 1 pM to about 4 pM, about 1.5 pM to about 4 pM, about 2 pM to about 4 pM, about 2.5 pM to about 4 pM, about 3 pM to about 4 pM, about 3.5 pM to about 4 pM, about 0.01 pM to about 2 pM, about 0.05 pM to about 2 pM, about 0.1 pM to about 2 pM, about 0.15 pM to about 2 pM, about 0.2 pM to about 2 pM, about 0.25 pM to about 2 pM, about 0.3 pM to about 2 pM, about 0.35 pM to about 2 pM, about 0.4 pM to about 2 pM, about 0.45 pM to about 2 pM, about 0.5 pM to about 2 pM, about 0.55 pM to about 2 pM, about 0.6 pM to about 2 pM, about 0.65 pM to about 2 pM, about 0.7 pM to about 2 pM, about 0.75 pM to about 2 pM, about 0.8 pM to about 2 pM, about 0.85 pM to about 2 pM, about 0.9 pM to about 2 pM, about 0.95 pM to about 2 pM, about 1 pM to about 2 pM, about 1.5 pM to about 2 pM, about 0.01 pM to about 1 pM, about 0.05 pM to about 1 pM, about 0.1 pM to about 1 pM, about 0.15 pM to about 1 pM, about 0.2 pM to about 1 pM, about 0.25 pM to about 1 pM, about 0.3 pM to about 1 pM, about 0.35 pM to about 1 pM, about 0.4 pM to about 1 pM, about 0.45 pM to about 1 pM, about 0.5 pM to about 1 pM, about 0.55 pM to about 1 pM, about 0.6 pM to about 1 pM, about 0.65 pM to about 1 pM, about 0.7 pM to about 1 pM, about 0.75 pM to about 1 pM, about 0.8 pM to about 1 pM, about 0.85 pM to about 1 pM, about 0.9 pM to about 1 pM, about 0.95 pM to about 1 pM, about 0.01 pM to about 0.8 pM, about 0.05 pM to about 0.8 pM, about 0.1 pM to about 0.8 pM, about 0.15 pM to about 0.8 pM, about 0.2 pM to about 0.8 pM, about 0.25 pM to about 0.8 pM, about 0.3 pM to about 0.8 pM, about 0.35 pM to about 0.8 pM, about 0.4 pM to about 0.8 pM, about 0.45 pM to about 0.8 pM, about 0.5 pM to about 0.8 pM, about 0.55 pM to about 0.8 pM, about 0.6 pM to about 0.8 pM, about 0.65 pM to about 0.8 pM, about 0.7 pM to about 0.8 pM, about 0.75 pM to about 0.8 pM, about 0.01 pM to about 0.6 pM, about 0.05 pM to about 0.6 pM, about 0.1 pM to about 0.6 pM, about 0.15 pM to about 0.6 pM, about 0.2 pM to about 0.6 pM, about 0.25 pM to about 0.6 pM, about 0.3 pM to about 0.6 pM, about 0.35 pM to about 0.6 pM, about 0.4 pM to about 0.6 pM, about 0.45 pM to about 0.6 pM, about 0.5 pM to about 0.6 pM, about 0.55 pM to about 0.6 pM, about 0.01 pM to about 0.4 pM, about 0.05 pM to about 0.4 pM, about 0.1 pM to about 0.4 pM, about 0.15 pM to about 0.4 pM, about 0.2 pM to about 0.4 pM, about 0.25 pM to about 0.4 pM, about 0.3 pM to about 0.4 pM,Attorney Docket No: 134524-5009- WOabout 0.35 pM to about 0.4 pM, about 0.01 pM to about 0.2 pM, about 0.05 pM to about 0.2 pM, about 0.1 pM to about 0.2 pM, about 0.15 pM to about 0.2 pM, or about 0.05 pM to about 0.1 pM. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to IL-13 with a KDof about 0.01 pM, about 0.02 pM, about 0.03 pM, about 0.04 pM, about 0.05 pM, about 0.06 pM, about 0.07 pM, about 0.08 pM, about 0.09 pM, about 0.1 pM, about 0.11 pM, about 0.12 pM, about 0.13 pM, about 0.14 pM, about 0.15 pM, about 0.2 pM, about 0.3 pM, about 0.4 pM, about 0.5 pM, about 0.6 pM, about 0.7 pM, about 0.8 pM, about 0.9 pM, about 1 pM, about 2.5 pM, about 5 pM, about 7.5 pM, or about 10 pM.

[0320] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds (e.g., has a binding affinity for, has a binding specificity for) to IL-13.

[0321] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is characterized as having neutralizing activity against IL-13 (e.g., a full-length human IL-13). In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is characterized as having inhibitory activity against IL-13-mediated signaling.

[0322] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, binds to an epitope in an IL-13 protein (e.g., in a full-length human IL-13).

[0323] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, competes with a Reference Antibody (e.g., Lebrikizumab) for binding to IL-13. Techniques and assays for assessing competition between antibodies are known.

[0324] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces binding of IL-13 to its cognate receptor, IL-13R (IL-13Ra1 alone, IL-4Ro alone or their heterodimeric complex). In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces binding of IL-13 to IL-13R with an IC50of about 0.1 pM to about 500 pM, about 0.2 pM to about 500 pM, about 0.3 pM to about 500 pM, about 0.4 pM to about 500 pM, about 0.5 pM to about 500 pM, about 0.6 pM to about 500 pM, about 0.7 pM to about 500 pM, about 0.8 pM to about 500 pM, about 0.9 pM to about 500 pM, about 1 pM to about 500 pM, about 5 pM to about 500 pM, about 10 pM to about 500 pM, about 50 pM to about 500 pM, about 100 pM to about 500 pM, about 200 pM to about 500 pM, about 300 pM to about 500 pM, about 400 to about 500 pM, about 0.1 pM to about 300 pM, about 0.2 pM to about 300 pM, about 0.3 pM to about 300 pM, about 0.4 pM to about 300 pM, about 0.5 pM to about 300 pM, about 0.6 pM to about 300 pM, about 0.7 pM to about 300 pM, about 0.8 pM to about 300 pM, about 0.9 pM to about 300 pM, about 1 pM to about 300 pM, about 5 pM to aboutAttorney Docket No: 134524-5009- WO300 pM, about 10 pM to about 300 pM, about 50 pM to about 300 pM, about 100 pM to about 300 pM, about 200 pM to about 300 pM, about 0.1 pM to about 100 pM, about 0.2 pM to about 100 pM, about 0.3 pM to about 100 pM, about 0.4 pM to about 100 pM, about 0.5 pM to about 100 pM, about 0.6 pM to about 100 pM, about 0.7 pM to about 100 pM, about 0.8 pM to about 100 pM, about 0.9 pM to about 100 pM, about 1 pM to about 100 pM, about 5 pM to about 100 pM, about 10 pM to about 100 pM, about 50 pM to about 100 pM, about 0.1 pM to about 10 pM, about 0.2 pM to about 10 pM, about 0.3 pM to about 10 pM, about 0.4 pM to about 10 pM, about 0.5 pM to about 10 pM, about 0.6 pM to about 10 pM, about 0.7 pM to about 10 pM, about 0.8 pM to about 10 pM, about 0.9 pM to about 10 pM, about 1 pM to about 10 pM, about 5 pM to about 10 pM, about 0.1 pM to about 1 pM, about 0.2 pM to about 1 pM, about 0.3 pM to about 1 pM, about 0.4 pM to about 1 pM, about 0.5 pM to about 1 pM, about 0.6 pM to about 1 pM, about 0.7 pM to about 1 pM, about 0.8 pM to about 1 pM, about 0.9 pM to about 1 pM, about 0.1 pM to about 0.5 pM, about 0.2 pM to about 0.5 pM, about 0.3 pM to about 0.5 pM, or about 0.4 pM to about 0.5 pM. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces binding of IL-13 to IL-13R with an IC50of about 0.1 pM, about 0.5 pM, about 1 pM, about 5 pM, about 10 pM, about 50 pM, about 100 pM, or about 500 pM or less.

[0325] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces binding of IL-13 to IL-13R by about 10% to about 100%, about 15% to about 100%, about 20% to about 100%, about 25% to about 100%, about 30% to about 100%, about 35% to about 100%, about 40% to about 100%, about 45% to about 100%, about 50% to about 100%, about 55% to about 100%, about 60% to about 100%, about 65% to about 100%, about 70% to about 100%, about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, about 10% to about 90%, about 15% to about 90%, about 20% to about 90%, about 25% to about 90%, about 30% to about 90%, about 35% to about 90%, about 40% to about 90%, about 45% to about 90%, about 50% to about 90%, about 55% to about 90%, about 60% to about 90%, about 65% to about 90%, about 70% to about 90%, about 75% to about 90%, about 80% to about 90%, about 85% to about 90%, about 10% to about 80%, about 15% to about 80%, about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 55% to about 80%, about 60% to about 80%, about 65% to about 80%, about 70% to about 80%, about 75% to about 80%, about 10% to about 60%, about 15% to about 60%, about 20% to about 60%, about 25% to about 60%, about 30% to about 60%, about 35% to about 60%, about 40% to about 60%, about 45% to about 60%, about 50% to about 60%, about 55% to about 60%, about 10% to about 40%, about 15% to about 40%, aboutAttorney Docket No: 134524-5009- WO20% to about 40%, about 25% to about 40%, about 30% to about 40%, about 35% to about 40%, about 10% to about 20%, or about 15% to about 20%. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces binding of IL-13 to IL-13R by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%.

[0326] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, modulates (e.g., reduces, inhibits, neutralizes) an IL-13-mediated biological activity. Non-limiting examples of IL-13-mediated biological activities include: IL-13R-binding; IL-13-induced signal transducer and activator of transcription 6 (STAT6) signaling; IL-13-induced insulin receptor substrate 2 (IRS2) signaling; IL-13-induced STAT6 tyrosine phosphorylation; IL-13-induced B cell proliferation; IL-13-induced interferon-gamma synthesis; IL-13-induced activation of eosinophils, basophils, and / or mast cells; IL-13-induced inflammation; and dendritic cell activation. In some embodiments, an IL-13-mediated biological activity comprises one or more innate immune mechanisms of action and / or one or more adaptive immune mechanisms of action.

[0327] IL-13-mediated biological activities can be determined, for example, by measuring STAT6 reporter activity.

[0328] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, neutralizes a biological activity mediated by IL-13. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, neutralizes an IL-13-mediated biological activity with an IC50 of about 0.1 pM to about 500 pM, about 0.2 pM to about 500 pM, about 0.3 pM to about 500 pM, about 0.4 pM to about 500 pM, about 0.5 pM to about 500 pM, about 0.6 pM to about 500 pM, about 0.7 pM to about 500 pM, about 0.8 pM to about 500 pM, about 0.9 pM to about 500 pM, about 1 pM to about 500 pM, about 5 pM to about 500 pM, about 10 pM to about 500 pM, about 50 pM to about 500 pM, about 100 pM to about 500 pM, about 200 pM to about 500 pM, about 300 pM to about 500 pM, about 400 to about 500 pM, about 0.1 pM to about 300 pM, about 0.2 pM to about 300 pM, about 0.3 pM to about 300 pM, about 0.4 pM to about 300 pM, about 0.5 pM to about 300 pM, about 0.6 pM to about 300 pM, about 0.7 pM to about 300 pM, about 0.8 pM to about 300 pM, about 0.9 pM to about 300 pM, about 1 pM to about 300 pM, about 5 pM to about 300 pM, about 10 pM to about 300 pM, about 50 pM to aboutAttorney Docket No: 134524-5009- WO300 pM, about 100 pM to about 300 pM, about 200 pM to about 300 pM, about 0.1 pM to about 100 pM, about 0.2 pM to about 100 pM, about 0.3 pM to about 100 pM, about 0.4 pM to about 100 pM, about 0.5 pM to about 100 pM, about 0.6 pM to about 100 pM, about 0.7 pM to about 100 pM, about 0.8 pM to about 100 pM, about 0.9 pM to about 100 pM, about 1 pM to about 100 pM, about 5 pM to about 100 pM, about 10 pM to about 100 pM, about 50 pM to about 100 pM, about 0.1 pM to about 10 pM, about 0.2 pM to about 10 pM, about 0.3 pM to about 10 pM, about 0.4 pM to about 10 pM, about 0.5 pM to about 10 pM, about 0.6 pM to about 10 pM, about 0.7 pM to about 10 pM, about 0.8 pM to about 10 pM, about 0.9 pM to about 10 pM, about 1 pM to about 10 pM, about 5 pM to about 10 pM, about 0.1 pM to about 1 pM, about 0.2 pM to about 1 pM, about 0.3 pM to about 1 pM, about 0.4 pM to about 1 pM, about 0.5 pM to about 1 pM, about 0.6 pM to about 1 pM, about 0.7 pM to about 1 pM, about 0.8 pM to about 1 pM, about 0.9 pM to about 1 pM, about 0.1 pM to about 0.5 pM, about 0.2 pM to about 0.5 pM, about 0.3 pM to about 0.5 pM, or about 0.4 pM to about 0.5 pM. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, neutralizes an IL-13-mediated biological activity with an IC50 of about 0.1 pM, about 0.5 pM, about 1 pM, about 5 pM, about 10 pM, about 50 pM, about 100 pM, or about 500 pM or less.

[0329] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces an IL-13-mediated biological activity by about 10% to about 100%, about 15% to about 100%, about 20% to about 100%, about 25% to about 100%, about 30% to about 100%, about 35% to about 100%, about 40% to about 100%, about 45% to about 100%, about 50% to about 100%, about 55% to about 100%, about 60% to about 100%, about 65% to about 100%, about 70% to about 100%, about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, about 10% to about 90%, about 15% to about 90%, about 20% to about 90%, about 25% to about 90%, about 30% to about 90%, about 35% to about 90%, about 40% to about 90%, about 45% to about 90%, about 50% to about 90%, about 55% to about 90%, about 60% to about 90%, about 65% to about 90%, about 70% to about 90%, about 75% to about 90%, about 80% to about 90%, about 85% to about 90%, about 10% to about 80%, about 15% to about 80%, about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 55% to about 80%, about 60% to about 80%, about 65% to about 80%, about 70% to about 80%, about 75% to about 80%, about 10% to about 60%, about 15% to about 60%, about 20% to about 60%, about 25% to about 60%, about 30% to about 60%, about 35% to about 60%, about 40% to about 60%, about 45% to about 60%, about 50% to about 60%, about 55% to about 60%, about 10% to about 40%, about 15% to aboutAttorney Docket No: 134524-5009- WO40%, about 20% to about 40%, about 25% to about 40%, about 30% to about 40%, about 35% to about 40%, about 10% to about 20%, or about 15% to about 20%. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces an IL-13-mediated biological activity by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%.

[0330] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces one or more of IL-13-induced signal transducer and activator of transcription 6 (STAT6) signaling; IL-13-induced insulin receptor substrate 2 (IRS2) signaling; IL-13-induced STAT6 tyrosine phosphorylation; IL-13-induced B cell proliferation; IL-13-induced interferon-gamma synthesis; IL-13-induced activation of eosinophils, basophils, and / or mast cells; and IL-13-mediated inflammation by at least about 10% to about 100%, about 15% to about 100%, about 20% to about 100%, about 25% to about 100%, about 30% to about 100%, about 35% to about 100%, about 40% to about 100%, about 45% to about 100%, about 50% to about 100%, about 55% to about 100%, about 60% to about 100%, about 65% to about 100%, about 70% to about 100%, about 75% to about 100%, about 80% to about 100%, about 85% to about 100%, about 90% to about 100%, about 95% to about 100%, about 10% to about 90%, about 15% to about 90%, about 20% to about 90%, about 25% to about 90%, about 30% to about 90%, about 35% to about 90%, about 40% to about 90%, about 45% to about 90%, about 50% to about 90%, about 55% to about 90%, about 60% to about 90%, about 65% to about 90%, about 70% to about 90%, about 75% to about 90%, about 80% to about 90%, about 85% to about 90%, about 10% to about 80%, about 15% to about 80%, about 20% to about 80%, about 25% to about 80%, about 30% to about 80%, about 35% to about 80%, about 40% to about 80%, about 45% to about 80%, about 50% to about 80%, about 55% to about 80%, about 60% to about 80%, about 65% to about 80%, about 70% to about 80%, about 75% to about 80%, about 10% to about 60%, about 15% to about 60%, about 20% to about 60%, about 25% to about 60%, about 30% to about 60%, about 35% to about 60%, about 40% to about 60%, about 45% to about 60%, about 50% to about 60%, about 55% to about 60%, about 10% to about 40%, about 15% to about 40%, about 20% to about 40%, about 25% to about 40%, about 30% to about 40%, about 35% to about 40%, about 10% to about 20%, or about 15% to about 20%. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, reduces one or more T2 adaptive immuneAttorney Docket No: 134524-5009- WOresponse induced by IL-13 by at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%.IV. Reference Antibody

[0331] As used herein, the term "reference" or "reference antibody" refers to an antibody (e.g., immunoglobulin molecule) that specifically binds to an IL-13 protein (e.g., a polypeptide comprising an amino acid sequence of SEQ ID NO: 161 and / or SEQ ID NO: 212) and is used as a comparison for an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof.

[0332] In some embodiments, a reference antibody may be used as a comparator to characterize one or more structural differences of an anti-IL-13 antibody disclosed herein, or an antigen-binding fragment thereof.

[0333] In some embodiments, a reference antibody may be used as a comparator to characterize one of more pharmacokinetic property of an anti-IL-13 antibody disclosed herein, or an antigen-binding fragment thereof. In some embodiments, a reference antibody may be used as a comparator to characterize a dissociation constant (KD) of an anti-IL-13 antibody disclosed herein, or an antigen-binding fragment thereof. In some embodiments, a reference antibody may be used as a comparator to characterize a dissociation constant (KD) of an anti-IL-13 antibody disclosed herein, or an antigen-binding fragment thereof.

[0334] In some embodiments, a reference antibody may be used as a comparator to characterize an effective concentration of an anti-IL-13 antibody disclosed herein, or antigenbinding fragment thereof, needed to detectably bind an IL-13 polypeptide. For example, in some embodiments, a reference antibody may be used as a comparator to characterize a half-maximal effective concentration (EC50) needed for an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, to bind an IL-13 polypeptide. In some embodiments, a reference antibody may be used as a comparator to characterize an 80%-maximal effective concentration (EC80) needed for an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, to bind an IL-13 polypeptide. In some embodiments, a reference antibody may be used as a comparator to characterize a 90%-maximal effective concentration (EC90) needed for an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, to bind an IL-13 polypeptide.Attorney Docket No: 134524-5009- WO

[0335] In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, in achieving a particular biological outcome in an in vitro assay. In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13 antibody disclosed herein, to inhibit the activity of IL-13 in an in vitro reporter assay. For example, a reference antibody may be used as a comparator to characterize the binding kinetics of an antibody disclosed herein, or antigen-binding fragment thereof, using an assay disclosed herein in Examples 1 to 5 or Examples 7 to 9. For example, a reference antibody may be used as a comparator to characterize the half-maximal concentration (e.g., IC50) of an antibody disclosed herein, or antigen-binding fragment thereof, using an assay disclosed herein in Example 2.

[0336] In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, in achieving a particular biological outcome in an in vitro cell-based assay. In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, to inhibit the IL-13-activated release of one or more cytokine and / or chemokine. In some embodiments, a reference antibody may be used as a comparator to characterize the half-maximal concentration (e.g., IC50) of an antibody disclosed herein, or antigen-binding fragment thereof, needed to inhibit IL-13-activated release of one or more cytokine and / or chemokine from peripheral blood mononuclear cells (PBMCs). In some embodiments, a reference antibody may be used as a comparator to characterize the half-maximal concentration (e g., IC50) of an antibody disclosed herein, or antigen-binding fragment thereof.

[0337] In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, in achieving a particular biological outcome in an in vivo model of a chronic inflammatory disease. In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, in achieving a particular biological outcome in an in vivo model of allergic asthma. In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof, at inhibiting: total serum levels of IgE, serum levels of antigen-specific IgE (e.g., ovalbumin (OVA-specific IgE)), or a combination thereof, in a murine model of eczema. In some embodiments, a reference antibody may be used as a comparator to characterize the efficacy of an anti-IL-13Attorney Docket No: 134524-5009- WOantibody disclosed herein, or antigen-binding fragment thereof, at one or more of IL-13-induced signal transducer and activator of transcription 6 (STAT6) signaling; IL-13-induced insulin receptor substrate 2 (IRS2) signaling; IL-13-induced STAT6 tyrosine phosphorylation; IL-13-induced B cell proliferation; IL-13-induced interferon-gamma synthesis; IL-13-induced activation of eosinophils, basophils, and / or mast cells.

[0338] In some embodiments, a reference antibody may be used as a comparator to characterize the plasma half-life of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof. In some embodiments, a reference antibody may be used as a comparator to characterize the plasma half-life of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof when administered (e.g., intravenously, subcutaneously, intraperitoneally, intranasally) to a subject (e.g., human, non-human primate (e.g., cynomolgus monkey)). In some embodiments, a reference antibody may be used as a comparator to characterize the pharmacokinetic and / or physiologically based pharmacokinetic profile of an anti-IL-13 antibody disclosed herein, or antigen-binding fragment thereof in an in silico prediction model.

[0339] In some embodiments, a reference antibody comprises:a) a heavy chain complementarity determining region 1 (HCDR1), a heavy chain complementarity determining region 2 (HCDR2), and a heavy chain complementarity determining region 3 (HCDR3) sequence of SEQ ID NO: 213, SEQ ID NO: 214 and SEQ ID NO: 215, respectively; and / or(b) a light chain complementarity determining region 1 (LCDR1), a light chain complementarity determining region 2 (LCDR2), and a light chain complementarity determining region 3 (LCDR3) sequence of SEQ ID NO: 216, SEQ ID NO: 217, and SEQ ID NO: 218, respectively.

[0340] In some embodiments, a reference antibody comprises:a) a HCDR1, a HCDR2, and a HCDR3 sequence of SEQ ID NO: 213, SEQ ID NO:214 and SEQ ID NO: 215, respectively; andb) a LCDR1, a LCDR2, and a LCDR3 sequence of 216, SEQ ID NO: 217, and SEQ ID NO: 218, respectively.

[0341] In some embodiments, a reference antibody comprises:a) an immunoglobulin heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 219; and / orb) an immunoglobulin light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 220.Attorney Docket No: 134524-5009- WO

[0342] In some embodiments, a reference antibody comprises:a) an immunoglobulin heavy chain variable domain (VH) comprising the amino acid sequence of SEQ ID NO: 219; andb) an immunoglobulin light chain variable domain (VL) comprising the amino acid sequence of SEQ ID NO: 220.

[0343] In some embodiments, a reference antibody comprises:a) an immunoglobulin heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 221; andb) an immunoglobulin light chain (LC) comprising the amino acid sequence of SEQ ID NO: 222.

[0344] Table 7 provides the sequences complementarity determining regions (CDRs), heavy chain variable domain (VH), light chain variable domain (VL), heavy chain (HC), and light chain variable domain (LC) of an illustrative reference antibody.Table 7: Reference anti-IL-13 Antibody SequencesSequence Amino Acid Sequence SEQ ID NO:HCDR1 AYSVN 213 HCDR2 MIWGDGKIVYNSALKS 214 HCDR3 DGYYPYAMDN 215 LCDR1 RASKSVDSYGNSFMH 216 LCDR2 LASNLES 217 LCDR3 QQNNEDPRT 218VH QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALE 219WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTAT YYCAGDGYYPYAMDNWGQGSLVTVSS VL DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKP 220GQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVY YCQQNNEDPRTFGGGTKVEIKR HC QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALE 221WLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATAttorney Docket No: 134524-5009- WOSequence Amino Acid Sequence SEQ ID NO:YYCAGDGYYPYAMDNWGQGSLVTVSSASTKGPSVFPLAPCSRST SESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPP CPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQ FNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKE YKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQV SLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYS RLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLG LC DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKP 222GQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVY YCQQNNEDPRTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASV VCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLS STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECV. Nucleic Acids, Vectors, Host Cells

[0345] In some embodiments, the present disclosure provides one or more polynucleotides (e.g., DNA, RNA, or analogs thereof) encoding any antibody disclosed herein, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is encoded by a single polynucleotide. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is encoded by two or more polynucleotides.

[0346] In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is encoded by one or more linear polynucleotides. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is encoded by one or more circular polynucleotides. In some embodiments, an antibody of the present disclosure, or antigen-binding fragment thereof, is encoded by one or more circular RNAs (circRNAs). In some embodiments, a circRNA comprises one or more ribozyme sequences. In some embodiments, a ribozyme sequence is activated for autocleavage in a host cell, thereby resulting in linearization of a circRNA.

[0347] In some embodiments, one or more polynucleotides (e.g., DNA, RNA, or analogs thereof) encoding an antibody of the present disclosure, antigen-binding fragment thereof, orAttorney Docket No: 134524-5009- WOpolypeptide chain (e.g., HC or LC) thereof, incorporates one or more modified nucleotide. In some embodiments, a modified nucleotide results from a chemical modification of a nucleobase, backbone, or combination thereof. In some embodiments, a chemically modified polynucleotide (e.g., RNA, mRNA) comprises one or more anti-reverse cap analogs (ARCA): m27.3'-OGP3G, GP3G (Unmethylated Cap Analog), m7GP3G (Monomethylated Cap Analog), m32.2.7GP3G (Trimethylated Cap Analog), m5CTP (5'-methyl-cytidine triphosphate), m6ATP (N6-methyl-adenosine-5'-triphosphate), s2UTP (2-thio-uridine triphosphate), and 'P (pseudouridine triphosphate).

[0348] In some embodiments, one or more polynucleotides (e.g., DNA, RNA, or analogs thereof) encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof, incorporates one or more nucleosides selected from dihydrouridine, inosine, 7-methylguanosine, 5-methylcytidine (5mC), 5' Phosphate ribothymidine, 2'-O-methyl ribothymidine, 2'-0-ethyl ribothymidine, 2'-fluoro ribothymidine, C-5 propynyl-deoxycytidine (pdC), C-5 propynyl-deoxyuridine (pdU), C-5 propynyl-cytidine (pC), C-5 propynyl-uridine (pU), 5-methyl cytidine, 5-methyl uridine, 5-methyl deoxycytidine, 5-methyl deoxyuridine methoxy, 2,6-diaminopurine, 5'-Dimethoxytrityl-N4-ethyl-2'-deoxycytidine, C-5 propynyl-f-cytidine (pfC), C-5 propynyl-f-uridine (pfU), 5-methyl f-cytidine, 5-methyl f-uridine, C-5 propynyl-m-cytidine (pmC), C-5 propynyl-f-uridine (pmU), 5-methyl m-cytidine, 5-methyl m-uridine, LNA (locked nucleic acid), MGB (minor groove binder) pseudouridine (^P), 1-N-methylpseudouridine (1-Me-Ψ), and 5-methoxyuridine (5-MO-U). In some embodiments, a polynucleotide of the present disclosure comprises one or more locked nucleotides.

[0349] In some embodiments, one or more polynucleotides encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof, comprises a sequence that is codon optimized for human expression. In some embodiments, codon optimization may be performed such that codons for which frequently occurring tRNAs are available are inserted in place of “rare codons.” In some embodiments, codon-optimization may include increasing guanosine / cytosine (G / C) content of a coding region of a polyribonucleotide described herein as compared to the G / C content of the corresponding coding sequence of a wild-type or reference polyribonucleotide. In some embodiments, codonoptimization may include increasing guanosine / cytosine (G / C) content of a coding region of a polyribonucleotide described herein as compared to the G / C content of the corresponding coding sequence of a wild-type or reference polyribonucleotide, wherein the amino acid sequenceAttorney Docket No: 134524-5009- WOencoded by the polyribonucleotide is not modified compared to the amino acid sequence. In some embodiments, a coding sequence is codon optimized for expression in a particular cell or tissue.

[0350] In some embodiments, the present disclosure provides a vector (e.g., an expression vector, including a viral-delivery vector) comprising one or more polynucleotides encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof.

[0351] As used herein, the term “expression vector” refers to a replicable nucleic acid from which one or more polypeptides can be expressed when the expression vector is transformed into a suitable expression host cell.

[0352] Various expression vectors can be employed to express a polynucleotide encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof. Both viral-based and nonviral expression vectors can be used to produce antibodies in a mammalian host cell. Non-viral vectors and systems include plasmids, episomal vectors, typically with an expression cassette for expressing a protein or RNA, and human artificial chromosomes. In some embodiments, nonviral vectors useful forexpression of an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof in mammalian (e.g., human) cells include pThioHis A, B & C, pcDNA3.1 / His, pEBVHis A, B & C, MPSV vectors, and numerous other known vectors for protein expression. In some embodiments, viral vectors include vectors based on retroviruses, adenoviruses, adeno-associated viruses, herpes viruses, vectors based on SV40, papilloma virus, HBP Epstein Barr virus, vaccinia virus vectors and Semliki Forest virus (SFV).

[0353] In some embodiments, a vector (e.g., expression vector) further comprises an expression control polynucleotide sequence operably linked to one or more polynucleotides encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof. In some embodiments, an expression control polynucleotide sequence comprises a promoter sequence, an enhancer sequence, a transcription terminator, or combination thereof. In some embodiments, an expression control polynucleotide sequence comprises an inducible promoter sequence. As used herein, the term “promoter” refers to a region of DNA to which RNA polymerase binds and initiates the transcription of a gene. As used herein, the term “operably linked” refers to a nucleic acid positioned in a recombinant polynucleotide (e.g., vector) in such a way that enables expression of a nucleic acid (e.g., a polynucleotide encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof) under control of the element (e.g., promoter) to which it is linked.Attorney Docket No: 134524-5009- WO

[0354] In some embodiments, a vector (e.g., expression vector) disclosed herein further comprises a polynucleotide sequence encoding a selectable marker. As used herein, the term “selectable marker” refers to an element that confers a trait suitable for artificial selection of a transformed or transduced cell. In some embodiments, selectable markers can be negative or positive selection markers.

[0355] Expression vectors can include expression control sequences, such as an origin of replication, a promoter, and an enhancer, and necessary processing information sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and transcriptional terminator sequences. These expression vectors usually contain promoters derived from genes from host cells (e.g., mammalian cells), or viral genes from viruses that target said host cells. Suitable promoters may be constitutive, cell type-specific, stage-specific, and / or modulatable or regulatable. Useful promoters include, but are not limited to, the metallothionein promoter, the constitutive adenovirus major late promoter, the dexamethasone-inducible MMTV promoter, the SV40 promoter, the MRP pollll promoter, the constitutive MPSV promoter, the tetracyclineinducible CMV promoter (such as the human immediate-early CMV promoter), the constitutive CMV promoter, and known promoter-enhancer combinations.

[0356] In some embodiments, the present disclosure provides host cells for harboring and expressing polynucleotides encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof. In some embodiments, a host cell can be prokaryotic or eukaryotic. For example, in some embodiments, E. coli is a prokaryotic host cell used for cloning and expressing the one or more polynucleotides encoding an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof. In some embodiments, other prokaryotic host cells are suitable for use including bacilli, such as Bacillus subtilis, and other enterobacteriaceae, such as Salmonella, Serratia, and various Pseudomonas species. In some embodiments, prokaryotic host cells can be used to propagate expression vectors, which typically contain expression control sequences compatible with a host cell (e.g., an origin of replication). In addition, any number of a variety of well-known promoters can be used, such as the lactose promoter system, a tryptophan (trp) promoter system, a betalactamase promoter system, or a promoter system from phage lambda. The promoters typically control expression, optionally with an operator sequence, and have ribosome binding site sequences for initiating and completing transcription and translation. In some embodiments, other cells, such as yeast (e.g., Pichia pastoris cells) and insect cells, can be used as host cells.Attorney Docket No: 134524-5009- WO

[0357] In some embodiments, mammalian cells are used as host cells to express and produce an antibody of the present disclosure, antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof. In some embodiments, a mammalian host cell can be either a hybridoma cell line expressing endogenous immunoglobulin genes or a mammalian cell line harboring an exogenous expression vector. Various suitable mammalian host cell lines have been developed that are capable of secreting intact immunoglobulins. In some embodiments, mammalian host cells used for expressing an antibody of the present disclosure, or antigen-binding fragment thereof, or polypeptide chain (e.g., HC or LC) thereof, includes Chinese hamster ovary (CHO) cells, COS cells, human embryonic kidney (HEK), HeLa cells, myeloma cell lines, transformed B-cells, and hybridomas.VI. Compositions

[0358] In some embodiments, the present disclosure provides a composition comprising an antibody disclosed herein, or antigen-binding fragment thereof. In some embodiments, a composition is a pharmaceutical composition.

[0359] In some embodiments, a composition (e.g., a pharmaceutical composition) further comprises one or more pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers (Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)). Suitable pharmaceutically acceptable carriers, excipients, or stabilizers are non-toxic to recipients at the dosages and concentrations employed. Non-limiting examples of pharmaceutically acceptable carriers, excipients, stabilizers, diluents or tonifiers include: buffers (e.g., phosphate, citrate, histidine); antioxidants (e.g., ascorbic acid or methionine); preservatives; proteins (e.g., serum albumin, gelatin); hydrophilic polymers; amino acids; carbohydrates (e.g., monosaccharides, disaccharides, glucose, mannose or dextrins); chelating agents (e.g., EDTA); sugars (e.g., sucrose, mannitol, trehalose or sorbitol); salt-forming counter-ions (e.g., sodium); metal complexes (e.g., Zn-protein complexes); non-ionic surfactants (e.g., Tween), PLURONICS™; and polyethylene glycol (PEG).

[0360] In some embodiments, a composition (e.g., a pharmaceutical composition) is formulated for a suitable administration schedule and route. In some embodiments, a composition (e.g., a pharmaceutical composition) is formulated for parenteral administration. Non-limiting examples of administration routes include subcutaneous, intravenous, intraperitoneal, oral, rectal, intranasal, mucosal, intramuscular, etc. In some embodiments, a composition (e.g., a pharmaceutical composition) is stored as an aqueous solution or as a dried formulation (e.g., lyophilized).Attorney Docket No: 134524-5009- WO

[0361] In some embodiments, a composition disclosed herein is formulated for subcutaneous administration. In some embodiments, a composition disclosed herein is formulated intravenous administration.

[0362] In some embodiments, a composition (e.g., a pharmaceutical composition) disclosed herein is provided in a dosage form, e.g., in a prefilled syringe or autoinjector.

[0363] In some embodiments, a composition (e.g., a pharmaceutical composition) comprises from about 10 mg to 1500 mg of an antibody of the present disclosure, or antigen-binding fragment thereof. In some embodiments, a composition (e.g., a pharmaceutical composition) comprises from about 10 mg to about 1500 mg, about 20 mg to about 1500 mg, about 30 mg to about 1500 mg, about 40 mg to about 1500 mg, about 50 mg to about 1500 mg, about 60 mg to about 1500 mg, about 70 mg to about 1500 mg, about 80 mg to about 1500 mg, about 90 mg to about 1500 mg, about 100 mg to about 1500 mg, about 150 mg to about 1500 mg, about 200 mg to about 1500 mg, about 250 mg to about 1500 mg, about 300 mg to about 1500 mg, about 350 mg to about 1500 mg, about 400 mg to about 1500 mg, about 450 mg to about 1500 mg, about 500 mg to about 1500 mg, about 550 mg to about 1500 mg, about 600 mg to about 1500 mg, about 650 mg to about 1500 mg, about 700 mg to about 1500 mg, about 750 mg to about 1500 mg, about 800 mg to about 1500 mg, about 850 mg to about 1500 mg, about 900 mg to about 1500 mg, about 950 mg to about 1500 mg, about 1000 mg to about 1500 mg, about 1050 mg to about 1500 mg, about 1100 mg to about 1500 mg, about 1150 mg to about 1500 mg, about 1200 mg to about 1500 mg, about 1250 mg to about 1500 mg, about 1300 mg to about 1500 mg, about 1350 mg to about 1500 mg, about 1400 mg to about 1500 mg, about 1450 mg to about 1500 mg, about 10 mg to about 1400 mg, about 20 mg to about 1400 mg, about 30 mg to about 1400 mg, about 40 mg to about 1400 mg, about 50 mg to about 1400 mg, about 60 mg to about 1400 mg, about 70 mg to about 1400 mg, about 80 mg to about 1400 mg, about 90 mg to about 1400 mg, about 100 mg to about 1400 mg, about 150 mg to about 1400 mg, about 200 mg to about 1400 mg, about 250 mg to about 1400 mg, about 300 mg to about 1400 mg, about 350 mg to about 1400 mg, about 400 mg to about 1400 mg, about 450 mg to about 1400 mg, about 500 mg to about 1400 mg, about 550 mg to about 1400 mg, about 600 mg to about 1400 mg, about 650 mg to about 1400 mg, about 700 mg to about 1400 mg, about 750 mg to about 1400 mg, about 800 mg to about 1400 mg, about 850 mg to about 1400 mg, about 900 mg to about 1400 mg, about 950 mg to about 1400 mg, about 1000 mg to about 1400 mg, about 1050 mg to about 1400 mg, about 1100 mg to about 1400 mg, about 1150 mg to about 1400 mg, about 1200 mg to about 1400 mg, about 1250 mg to about 1400 mg, about 1300 mg to about 1400 mg, about 1350 mg to aboutAttorney Docket No: 134524-5009- WO1400 mg, about 10 mg to about 1300 mg, 20 mg to about 1300 mg, 30 mg to about 1300 mg, 40 mg to about 1300 mg, 50 mg to about 1300 mg, about 60 mg to about 1300 mg, about 70 mg to about 1300 mg, about 80 mg to about 1300 mg, about 90 mg to about 1300 mg, about 100 mg to about 1300 mg, about 150 mg to about 1300 mg, about 200 mg to about 1300 mg, about 250 mg to about 1300 mg, about 300 mg to about 1300 mg, about 350 mg to about 1300 mg, about 400 mg to about 1300 mg, about 450 mg to about 1300 mg, about 500 mg to about 1300 mg, about 550 mg to about 1300 mg, about 600 mg to about 1300 mg, about 650 mg to about 1300 mg, about 700 mg to about 1300 mg, about 750 mg to about 1300 mg, about 800 mg to about 1300 mg, about 850 mg to about 1300 mg, about 900 mg to about 1300 mg, about 950 mg to about 1300 mg, about 1000 mg to about 1300 mg, about 1050 mg to about 1300 mg, about 1100 mg to about 1300 mg, about 1150 mg to about 1300 mg, about 1200 mg to about 1300 mg, about 1250 mg to about 1300 mg, about 10 mg to about 1200 mg, 20 mg to about 1200 mg, 30 mg to about 1200 mg, 40 mg to about 1200 mg, 50 mg to about 1200 mg, about 60 mg to about 1200 mg, about 70 mg to about 1200 mg, about 80 mg to about 1200 mg, about 90 mg to about 1200 mg, about 100 mg to about 1200 mg, about 150 mg to about 1200 mg, about 200 mg to about 1200 mg, about 250 mg to about 1200 mg, about 300 mg to about 1200 mg, about 350 mg to about 1200 mg, about 400 mg to about 1200 mg, about 450 mg to about 1200 mg, about 500 mg to about 1200 mg, about 550 mg to about 1200 mg, about 600 mg to about 1200 mg, about 650 mg to about 1200 mg, about 700 mg to about 1200 mg, about 750 mg to about 1200 mg, about 800 mg to about 1200 mg, about 850 mg to about 1200 mg, about 900 mg to about 1200 mg, about 950 mg to about 1200 mg, about 1000 mg to about 1200 mg, about 1050 mg to about 1200 mg, about 1100 mg to about 1200 mg, about 1150 mg to about 1200 mg, about 10 mg to about 1100 mg, 20 mg to about 1100 mg, 30 mg to about 1100 mg, 40 mg to about 1100 mg, 50 mg to about 1100 mg, about 60 mg to about 1100 mg, about 70 mg to about 1100 mg, about 80 mg to about 1100 mg, about 90 mg to about 1100 mg, about 100 mg to about 1100 mg, about 150 mg to about 1100 mg, about 200 mg to about 1100 mg, about 250 mg to about 1100 mg, about 300 mg to about 1100 mg, about 350 mg to about 1100 mg, about 400 mg to about 1100 mg, about 450 mg to about 1100 mg, about 500 mg to about 1100 mg, about 550 mg to about 1100 mg, about 600 mg to about 1100 mg, about 650 mg to about 1100 mg, about 700 mg to about 1100 mg, about 750 mg to about 1100 mg, about 800 mg to about 1100 mg, about 850 mg to about 1100 mg, about 900 mg to about 1100 mg, about 950 mg to about 1100 mg, about 1000 mg to about 1100 mg, about 1050 mg to about 1100 mg, about 10 mg to about 1000 mg, about 20 mg to about 1000 mg, about 30 mg to about 1000 mg, about 40 mg to about 1000 mg, about 50 mg to about 1000 mg, about 60 mg to about 1000 mg, about 70 mg to about 1000 mg, about 80 mg to about 1000Attorney Docket No: 134524-5009- WOmg, about 90 mg to about 1000 mg, about 100 mg to about 1000 mg, about 150 mg to about 1000 mg, about 200 mg to about 1000 mg, about 250 mg to about 1000 mg, about 300 mg to about 1000 mg, about 350 mg to about 1000 mg, about 400 mg to about 1000 mg, about 450 mg to about 1000 mg, about 500 mg to about 1000 mg, about 550 mg to about 1000 mg, about 600 mg to about 1000 mg, about 650 mg to about 1000 mg, about 700 mg to about 1000 mg, about 750 mg to about 1000 mg, about 800 mg to about 1000 mg, about 850 mg to about 1000 mg, about 900 mg to about 1000 mg, about 950 mg to about 1000 mg, about 10 mg to about 900 mg, about 20 mg to about 900 mg, about 30 mg to about 900 mg, about 40 mg to about 900 mg, about 50 mg to about 900 mg, about 60 mg to about 900 mg, about 70 mg to about 900 mg, about 80 mg to about 900 mg, about 90 mg to about 900 mg, about 100 mg to about 900 mg, about 150 mg to about 900 mg, about 200 mg to about 900 mg, about 250 mg to about 900 mg, about 300 mg to about 900 mg, about 350 mg to about 900 mg, about 400 mg to about 900 mg, about 450 mg to about 900 mg, about 500 mg to about 900 mg, about 550 mg to about 900 mg, about 600 mg to about 900 mg, about 650 mg to about 900 mg, about 700 mg to about 900 mg, about 750 mg to about 900 mg, about 800 mg to about 900 mg, about 850 mg to about 900 mg, about 10 mg to about 800 mg, about 20 mg to about 800 mg, about 30 mg to about 800 mg, about 40 mg to about 800 mg, about 50 mg to about 800 mg, about 60 mg to about 800 mg, about 70 mg to about 800 mg, about 80 mg to about 800 mg, about 90 mg to about 800 mg, about 100 mg to about 800 mg, about 150 mg to about 800 mg, about 200 mg to about 800 mg, about 250 mg to about 800 mg, about ...

Claims

Attorney Docket No: 134524-5009- WOWHAT IS CLAIMED IS:

1. A method of treating an IL-13-mediated disease in a subject, comprising:administering to the subject a therapeutically effective dose of about 10 mg to about 1500 mg of an antibody, or antigen-binding fragment thereof that binds interleukin-13 (IL-13) at an interval of about every 3 months to about every 12 months, wherein the antibody, or antigen-binding fragment thereof, comprises:a) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 4, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 6, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 1, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 3;b) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 10, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 12, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 7, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 9;c) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 16, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 17, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 18, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 13, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 14, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 15;d) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 22, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 23, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 24, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 19, aAttorney Docket No: 134524-5009- WOLCDR2 comprising the amino acid sequence of SEQ ID NO: 20, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 21;e) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 28, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 29, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 30, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 25, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 26, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 27;f) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 34, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 35, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 36, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 31, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 32, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 33;g) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 40, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 41, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 42, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 37, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 39;h) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 46, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 47, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 48, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 43, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 44, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 45;i) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 52, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 53, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 54, and a light chain complementarity determiningAttorney Docket No: 134524-5009- WOregion LCDR1 comprising the amino acid sequence of SEQ ID NO: 49, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 50, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 51;j) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 58, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 59, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 60, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 55, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 56, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 57;k) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 64, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 65, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 66, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 61, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 62, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 63;l) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 70, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 71, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 72, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 67, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 69;m) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 76, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 77, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 78, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 73, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 74, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 75;n) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 82, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 83, and a HCDR3 comprising the amino acidAttorney Docket No: 134524-5009- WOsequence of SEQ ID NO: 84, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 79, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 80, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 81;o) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 88, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 89, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 90, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 85, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 86, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 87; orp) a heavy chain complementarity determining region HCDR1 comprising the amino acid sequence of SEQ ID NO: 94, a HCDR2 comprising the amino acid sequence of SEQ ID NO: 95, and a HCDR3 comprising the amino acid sequence of SEQ ID NO: 96, and a light chain complementarity determining region LCDR1 comprising the amino acid sequence of SEQ ID NO: 91, a LCDR2 comprising the amino acid sequence of SEQ ID NO: 92, and a LCDR3 comprising the amino acid sequence of SEQ ID NO: 93.

2. The method of claim 1, wherein the effective dose is about 10 mg to about 1500 mg.

3. The method of claim 1 or 2, wherein the effective dose is about 200 mg to about 1400 mg.

4. The method of any one of claims 1 to 3, wherein the effective dose is about 250 mg to about 1300 mg.

5. The method of any one of claims 1 to 4, wherein the effective dose is about 300 mg to about 1200 mg.

6. The method of any one of claims 1 to 5, wherein the effective dose is about 300 mg.

7. The method of any one of claims 1 to 5, wherein the effective dose is about 600 mg.

8. The method of any one of claims 1 to 5, wherein the effective dose is about 1200 mg.Attorney Docket No: 134524-5009- WO9. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 3 months.

10. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 4 months.

11. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 6 months.

12. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 9 months.

13. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 12 months.

14. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 24 weeks.

15. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 26 weeks.

16. The method of any one of claims 1 to 8, wherein the effective dose is administered about every 28 weeks.

17. The method of any one of claims 1 to 16, wherein the effective dose is administered subcutaneously, intravenously, intramuscularly, or intraperitoneally.

18. The method of claim 17, wherein the effective dose is administered subcutaneously.

19. The method of any one of claims 1-18, wherein the effective dose is administered as a single 10 mg dose subcutaneously.Attorney Docket No: 134524-5009- WO20. The method of any one of claims 1-18, wherein the effective dose is administered as a single 30 mg dose subcutaneously.

21. The method of any one of claims 1-18, wherein the effective dose is administered as a single 100 mg dose subcutaneously.

22. The method of any one of claims 1-18, wherein the effective dose is administered as a single 300 mg dose subcutaneously.

23. The method of any one of claims 1-18, wherein the effective dose is administered as a single 600 mg dose subcutaneously.

24. The method of any one of claims 1-18, wherein the effective dose is administered as a single 1200 mg dose subcutaneously.

25. The method of any one of claims 1-18, wherein the effective dose is administered as two 100 mg doses subcutaneously.

26. The method of any one of claims 1-18, wherein the effective dose is administered as two 300 mg doses subcutaneously.

27. The method of any one of claims 1-18, wherein the effective dose is administered as two 600 mg doses subcutaneously.

28. The method of any one of claims 1-18, wherein the effective dose is administered as two 1200 mg doses subcutaneously.

29. The method of any one of claims 25-28, wherein the two 100 mg doses, the two 300 mg doses, the two 600 mg doses, or the two 1200 mg doses are administered on day 1 and day 15.

30. The method of any one of claims 1 to 28, wherein the IL-13-mediated disease is a chronic and / or an allergic inflammatory skin disease.Attorney Docket No: 134524-5009- WO31. The method of any one of claims 1 to 30, wherein the IL-13-mediated disease is selected from the group consisting of: asthma (including, but not limited to, mild asthma, mild to moderate asthma, moderate asthma, moderate to severe asthma, and / or severe asthma), allergic asthma, allergen-induced airway obstruction due to asthma and / or allergic asthma, atopic dermatitis (including, but not limited to, mild atopic dermatitis, mild to moderate atopic dermatitis, moderate atopic dermatitis, moderate-to-severe, and / or severe atopic dermatitis), eczema, acute urticaria, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), chronic obstructive airway disease, emphysema, chronic bronchitis, pulmonary fibrosis, systemic sclerosis, scleroderma, cryptogenic fibrosing alveolitis, usual interstitial pneumonitis, idiopathic interstitial pneumonitis, wound, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (SS), ulcerative colitis (UC), type 1 diabetes (T1D), Sjogren's syndrome (SS), prurigo nodularis, nasal polyposis, recurrent urticaria, aspergillosis, bullous pemphigoid, chronic sinusitis, alopecia areata, hay fever, pemphigus, allergic rhinitis, psoriasis, rosacea, allergic drug reactions, allergic reactions, anaphylaxis, acne, food allergies, inflammatory bowel disease (IBS), Crohn’s disease, ulcerative colitis, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis, eosinophilic colitis, eosinophilic gastritis, eosinophilic cystitis, eosinophilic fasciitis, eosinophilic pustular folliculitis, eosinophilic granulomatosis, eosinophilic polyangiitis, Churg-Strauss syndrome, biliary cancer, brain cancer, breast cancer, colorectal cancer, genitourinary cancer, head and neck cancer, liver cancer, Hodgkin's lymphoma, esophageal cancer, pancreatic cancer, prostate cancer, renal cancer, Kaposi's sarcoma, sinusitis, or chronic urticaria.

32. The method of any one of claims 1 to 31, wherein the IL-13-mediated disease is atopic dermatitis (AD).

33. The method of any one of claims 1 to 30, wherein the IL-13-mediated disease increases in itching, eczema, dry and scaly skin, red and inflamed patches, thickened skin, blistering, crusting, scaling, skin sensitivity, or combination thereof.

34. The method of any one of claims 1 to 33, wherein the subject is human.

35. The method of any one of claims 1 to 34, wherein the subject is an adult.Attorney Docket No: 134524-5009- WO36. The method of any one of claims 1-34, wherein the subject is a child.

37. The method of any one of claims 1 to 36, wherein administering the effective dose decreases the level of eosinophils in a blood, and / or urine sample from the subject as compared to a blood, and / or urine sample collected from the subject prior to administering.

38. The method of any one of claims 1 to 37, wherein administering the effective dose decreases the level of leukocytes in a blood, and / or urine sample from the subject as compared to a blood, and / or urine sample collected from the subject prior to administering.

39. The method of any one of claims 1 to 38, wherein administering the effective dose to the subject achieves a serum half-life of the antibody, or antigen-binding fragment thereof, in the subject of about 50 to about 150 days.

40. The method of claim 39, wherein the serum half-life of the antibody, or antigen-binding fragment thereof, in the subject is about 100 days.

41. The method of any one of claims 1 to 40, wherein administering the effective dose to the subject achieves a maximum serum concentration (Cmax) of the antibody, or antigenbinding fragment thereof, in the subject of about 3 µg / ml to about 300 µg / ml.

42. The method of any one of claims 1 to 41, wherein administering the effective dose to the subject achieves a serum AUC0-∞d value of the antibody, or antigen-binding fragment thereof, in the subject of about 10 µg·day / ml to about 1500 µg·day / ml.

43. The method of any one of claims 1 to 42, wherein the antibody, or antigen-binding fragment thereof comprises:a) a heavy chain variable region (VH) comprising an amino acid sequence of SEQ ID NO: 98, and a light chain variable region (VL) comprising an amino acid sequence of SEQ ID NO: 97;b) a VH comprising an amino acid sequence of SEQ ID NO: 100, and a VL comprising an amino acid sequence of SEQ ID NO: 99;Attorney Docket No: 134524-5009- WOc) a VH comprising an amino acid sequence of SEQ ID NO: 102, and a VL comprising an amino acid sequence of SEQ ID NO: 101;d) a VH comprising an amino acid sequence of SEQ ID NO: 104, and a VL comprising an amino acid sequence of SEQ ID NO: 103;e) a VH comprising an amino acid sequence of SEQ ID NO: 106, and a VL comprising an amino acid sequence of SEQ ID NO: 105;f) a VH comprising an amino acid sequence of SEQ ID NO: 108, and a VL comprising an amino acid sequence of SEQ ID NO: 107;g) a VH comprising an amino acid sequence of SEQ ID NO: 110, and a VL comprising an amino acid sequence of SEQ ID NO: 109;h) a VH comprising an amino acid sequence of SEQ ID NO: 112, and a VL comprising an amino acid sequence of SEQ ID NO: 111;i) a VH comprising an amino acid sequence of SEQ ID NO: 114, and a VL comprising an amino acid sequence of SEQ ID NO: 113;j) a VH comprising an amino acid sequence of SEQ ID NO: 116, and a VL comprising an amino acid sequence of SEQ ID NO: 115;k) a VH comprising an amino acid sequence of SEQ ID NO: 118, and a VL comprising an amino acid sequence of SEQ ID NO: 117;l) a VH comprising an amino acid sequence of SEQ ID NO: 120, and a VL comprising an amino acid sequence of SEQ ID NO: 119;m) a VH comprising an amino acid sequence of SEQ ID NO: 122, and a VL comprising an amino acid sequence of SEQ ID NO: 121;n) a VH comprising an amino acid sequence of SEQ ID NO: 124, and a VL comprising an amino acid sequence of SEQ ID NO: 123;o) a VH comprising an amino acid sequence of SEQ ID NO: 126, and a VL comprising an amino acid sequence of SEQ ID NO: 125; orp) a VH comprising an amino acid sequence of SEQ ID NO: 128, and a VL comprising an amino acid sequence of SEQ ID NO: 127.

44. The method of any one of claims 1 to 43, wherein the antibody is a human IgG 1 isotype antibody.

45. The method any one of claims 1 to 44, wherein the antibody comprises:Attorney Docket No: 134524-5009- WOa) a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 130, and a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 129; b) a HC comprising an amino acid sequence of SEQ ID NO: 132, and a LC comprising an amino acid sequence of SEQ ID NO: 131;c) a HC comprising an amino acid sequence of SEQ ID NO: 134, and a LC comprising an amino acid sequence of SEQ ID NO: 133;d) a HC comprising an amino acid sequence of SEQ ID NO: 136, and a LC comprising an amino acid sequence of SEQ ID NO: 135;e) a HC comprising an amino acid sequence of SEQ ID NO: 138, and a LC comprising an amino acid sequence of SEQ ID NO: 137;f) a HC comprising an amino acid sequence of SEQ ID NO: 140, and a LC comprising an amino acid sequence of SEQ ID NO: 139;g) a HC comprising an amino acid sequence of SEQ ID NO: 142, and a LC comprising an amino acid sequence of SEQ ID NO: 141;h) a HC comprising an amino acid sequence of SEQ ID NO: 144, and a LC comprising an amino acid sequence of SEQ ID NO: 143;i) a HC comprising an amino acid sequence of SEQ ID NO: 146, and a LC comprising an amino acid sequence of SEQ ID NO: 145;j) a HC comprising an amino acid sequence of SEQ ID NO: 148, and a LC comprising an amino acid sequence of SEQ ID NO: 147;k) a HC comprising an amino acid sequence of SEQ ID NO: 150, and a LC comprising an amino acid sequence of SEQ ID NO: 149;l) a HC comprising an amino acid sequence of SEQ ID NO: 152, and a LC comprising an amino acid sequence of SEQ ID NO: 151;m) a HC comprising an amino acid sequence of SEQ ID NO: 154, and a LC comprising an amino acid sequence of SEQ ID NO: 153;n) a HC comprising an amino acid sequence of SEQ ID NO: 156, and a LC comprising an amino acid sequence of SEQ ID NO: 155;o) a HC comprising an amino acid sequence of SEQ ID NO: 158, and a LC comprising an amino acid sequence of SEQ ID NO: 157;p) a HC comprising an amino acid sequence of SEQ ID NO: 160, and a LC comprising an amino acid sequence of SEQ ID NO: 159;q) a HC comprising an amino acid sequence of SEQ ID NO: 182, and a LC comprising an amino acid sequence of SEQ ID NO: 153;Attorney Docket No: 134524-5009- WOr) a HC comprising an amino acid sequence of SEQ ID NO: 183, and a LC comprising an amino acid sequence of SEQ ID NO: 147;s) a HC comprising an amino acid sequence of SEQ ID NO: 184, and a LC comprising an amino acid sequence of SEQ ID NO: 141;t) a HC comprising an amino acid sequence of SEQ ID NO: 185, and a LC comprising an amino acid sequence of SEQ ID NO: 153;u) a HC comprising an amino acid sequence of SEQ ID NO: 186, and a LC comprising an amino acid sequence of SEQ ID NO: 147;v) a HC comprising an amino acid sequence of SEQ ID NO: 187, and a LC comprising an amino acid sequence of SEQ ID NO: 141;w) a HC comprising an amino acid sequence of SEQ ID NO: 188, and a LC comprising an amino acid sequence of SEQ ID NO: 153;x) a HC comprising an amino acid sequence of SEQ ID NO: 189, and a LC comprising an amino acid sequence of SEQ ID NO: 147;y) a HC comprising an amino acid sequence of SEQ ID NO: 190, and a LC comprising an amino acid sequence of SEQ ID NO: 141;z) a HC comprising an amino acid sequence of SEQ ID NO: 191, and a LC comprising an amino acid sequence of SEQ ID NO: 153;aa) a HC comprising an amino acid sequence of SEQ ID NO: 192, and a LC comprising an amino acid sequence of SEQ ID NO: 147;bb) a HC comprising an amino acid sequence of SEQ ID NO: 193, and a LC comprising an amino acid sequence of SEQ ID NO: 141;cc) a HC comprising an amino acid sequence of SEQ ID NO: 194, and a LC comprising an amino acid sequence of SEQ ID NO: 153;dd) a HC comprising an amino acid sequence of SEQ ID NO: 195, and a LC comprising an amino acid sequence of SEQ ID NO: 147;ee) a HC comprising an amino acid sequence of SEQ ID NO: 196, and a LC comprising an amino acid sequence of SEQ ID NO: 141;ff) a HC comprising an amino acid sequence of SEQ ID NO: 197, and a LC comprising an amino acid sequence of SEQ ID NO: 153;gg) a HC comprising an amino acid sequence of SEQ ID NO: 198, and a LC comprising an amino acid sequence of SEQ ID NO: 147;hh) a HC comprising an amino acid sequence of SEQ ID NO: 199, and a LC comprising an amino acid sequence of SEQ ID NO: 141;Attorney Docket No: 134524-5009- WOii) a HC comprising an amino acid sequence of SEQ ID NO: 200, and a LC comprising an amino acid sequence of SEQ ID NO: 153;jj) a HC comprising an amino acid sequence of SEQ ID NO: 201, and a LC comprising an amino acid sequence of SEQ ID NO: 147;kk) a HC comprising an amino acid sequence of SEQ ID NO: 202, and a LC comprising an amino acid sequence of SEQ ID NO: 141;II) a HC comprising an amino acid sequence of SEQ ID NO: 203, and a LC comprising an amino acid sequence of SEQ ID NO: 153;mm) a HC comprising an amino acid sequence of SEQ ID NO: 204, and a LC comprising an amino acid sequence of SEQ ID NO: 147;nn) a HC comprising an amino acid sequence of SEQ ID NO: 205, and a LC comprising an amino acid sequence of SEQ ID NO: 141;oo) a HC comprising an amino acid sequence of SEQ ID NO: 206, and a LC comprising an amino acid sequence of SEQ ID NO: 153;pp) a HC comprising an amino acid sequence of SEQ ID NO: 207, and a LC comprising an amino acid sequence of SEQ ID NO: 147;qq) a HC comprising an amino acid sequence of SEQ ID NO: 208, and a LC comprising an amino acid sequence of SEQ ID NO: 141;rr) a HC comprising an amino acid sequence of SEQ ID NO: 209, and a LC comprising an amino acid sequence of SEQ ID NO: 153;ss) a HC comprising an amino acid sequence of SEQ ID NO: 210, and a LC comprising an amino acid sequence of SEQ ID NO: 147; ortt) a HC comprising an amino acid sequence of SEQ ID NO: 211, and a LC comprising an amino acid sequence of SEQ ID NO: 141.

46. A method of treating an IL-13-mediated disease in a human patient, comprising administering to the patient a therapeutically effective dose of about 10 mg to about 1200 mg of an antibody at an interval of about every 24 weeks to about every 28 weeks, wherein the antibody comprises:a) a heavy chain (HC) comprising an amino acid sequence of SEQ ID NO: 130, and a light chain (LC) comprising an amino acid sequence of SEQ ID NO: 129; b) a HC comprising an amino acid sequence of SEQ ID NO: 132, and a LC comprising an amino acid sequence of SEQ ID NO: 131;Attorney Docket No: 134524-5009- WOc) a HC comprising an amino acid sequence of SEQ ID NO: 134, and a LC comprising an amino acid sequence of SEQ ID NO: 133;d) a HC comprising an amino acid sequence of SEQ ID NO: 136, and a LC comprising an amino acid sequence of SEQ ID NO: 135;e) a HC comprising an amino acid sequence of SEQ ID NO: 138, and a LC comprising an amino acid sequence of SEQ ID NO: 137;f) a HC comprising an amino acid sequence of SEQ ID NO: 140, and a LC comprising an amino acid sequence of SEQ ID NO: 139;g) a HC comprising an amino acid sequence of SEQ ID NO: 142, and a LC comprising an amino acid sequence of SEQ ID NO: 141;h) a HC comprising an amino acid sequence of SEQ ID NO: 144, and a LC comprising an amino acid sequence of SEQ ID NO: 143;i) a HC comprising an amino acid sequence of SEQ ID NO: 146, and a LC comprising an amino acid sequence of SEQ ID NO: 145;j) a HC comprising an amino acid sequence of SEQ ID NO: 148, and a LC comprising an amino acid sequence of SEQ ID NO: 147;k) a HC comprising an amino acid sequence of SEQ ID NO: 150, and a LC comprising an amino acid sequence of SEQ ID NO: 149;l) a HC comprising an amino acid sequence of SEQ ID NO: 152, and a LC comprising an amino acid sequence of SEQ ID NO: 151;m) a HC comprising an amino acid sequence of SEQ ID NO: 154, and a LC comprising an amino acid sequence of SEQ ID NO: 153;n) a HC comprising an amino acid sequence of SEQ ID NO: 156, and a LC comprising an amino acid sequence of SEQ ID NO: 155;o) a HC comprising an amino acid sequence of SEQ ID NO: 158, and a LC comprising an amino acid sequence of SEQ ID NO: 157;p) a HC comprising an amino acid sequence of SEQ ID NO: 160, and a LC comprising an amino acid sequence of SEQ ID NO: 159;q) a HC comprising an amino acid sequence of SEQ ID NO: 182, and a LC comprising an amino acid sequence of SEQ ID NO: 153;r) a HC comprising an amino acid sequence of SEQ ID NO: 183, and a LC comprising an amino acid sequence of SEQ ID NO: 147;s) a HC comprising an amino acid sequence of SEQ ID NO: 184, and a LC comprising an amino acid sequence of SEQ ID NO: 141;Attorney Docket No: 134524-5009- WOt) a HC comprising an amino acid sequence of SEQ ID NO: 185, and a LC comprising an amino acid sequence of SEQ ID NO: 153;u) a HC comprising an amino acid sequence of SEQ ID NO: 186, and a LC comprising an amino acid sequence of SEQ ID NO: 147;v) a HC comprising an amino acid sequence of SEQ ID NO: 187, and a LC comprising an amino acid sequence of SEQ ID NO: 141;w) a HC comprising an amino acid sequence of SEQ ID NO: 188, and a LC comprising an amino acid sequence of SEQ ID NO: 153;x) a HC comprising an amino acid sequence of SEQ ID NO: 189, and a LC comprising an amino acid sequence of SEQ ID NO: 147;y) a HC comprising an amino acid sequence of SEQ ID NO: 190, and a LC comprising an amino acid sequence of SEQ ID NO: 141;z) a HC comprising an amino acid sequence of SEQ ID NO: 191, and a LC comprising an amino acid sequence of SEQ ID NO: 153;aa) a HC comprising an amino acid sequence of SEQ ID NO: 192, and a LC comprising an amino acid sequence of SEQ ID NO: 147;bb) a HC comprising an amino acid sequence of SEQ ID NO: 193, and a LC comprising an amino acid sequence of SEQ ID NO: 141;cc) a HC comprising an amino acid sequence of SEQ ID NO: 194, and a LC comprising an amino acid sequence of SEQ ID NO: 153;dd) a HC comprising an amino acid sequence of SEQ ID NO: 195, and a LC comprising an amino acid sequence of SEQ ID NO: 147;ee) a HC comprising an amino acid sequence of SEQ ID NO: 196, and a LC comprising an amino acid sequence of SEQ ID NO: 141;ff) a HC comprising an amino acid sequence of SEQ ID NO: 197, and a LC comprising an amino acid sequence of SEQ ID NO: 153;gg) a HC comprising an amino acid sequence of SEQ ID NO: 198, and a LC comprising an amino acid sequence of SEQ ID NO: 147;hh) a HC comprising an amino acid sequence of SEQ ID NO: 199, and a LC comprising an amino acid sequence of SEQ ID NO: 141;ii) a HC comprising an amino acid sequence of SEQ ID NO: 200, and a LC comprising an amino acid sequence of SEQ ID NO: 153;jj) a HC comprising an amino acid sequence of SEQ ID NO: 201, and a LC comprising an amino acid sequence of SEQ ID NO: 147;Attorney Docket No: 134524-5009- WOkk) a HC comprising an amino acid sequence of SEQ ID NO: 202, and a LC comprising an amino acid sequence of SEQ ID NO: 141;II) a HC comprising an amino acid sequence of SEQ ID NO: 203, and a LC comprising an amino acid sequence of SEQ ID NO: 153;mm) a HC comprising an amino acid sequence of SEQ ID NO: 204, and a LC comprising an amino acid sequence of SEQ ID NO: 147;nn) a HC comprising an amino acid sequence of SEQ ID NO: 205, and a LC comprising an amino acid sequence of SEQ ID NO: 141;oo) a HC comprising an amino acid sequence of SEQ ID NO: 206, and a LC comprising an amino acid sequence of SEQ ID NO: 153;pp) a HC comprising an amino acid sequence of SEQ ID NO: 207, and a LC comprising an amino acid sequence of SEQ ID NO: 147;qq) a HC comprising an amino acid sequence of SEQ ID NO: 208, and a LC comprising an amino acid sequence of SEQ ID NO: 141;rr) a HC comprising an amino acid sequence of SEQ ID NO: 209, and a LC comprising an amino acid sequence of SEQ ID NO: 153;ss) a HC comprising an amino acid sequence of SEQ ID NO: 210, and a LC comprising an amino acid sequence of SEQ ID NO: 147; ortt) a HC comprising an amino acid sequence of SEQ ID NO: 211, and a LC comprising an amino acid sequence of SEQ ID NO: 141.

47. The method of claim 46, comprising administering to the patient the therapeutically effective dose of:a) about 10 mg of the antibody at an interval of about every 24 weeks;b) about 10 mg of the antibody at an interval of about every 26 weeks;c) about 10 mg of the antibody at an interval of about every 6 months;d) about 10 mg of the antibody at an interval of about every 28 weeks;e) about 30 mg of the antibody at an interval of about every 24 weeks;f) about 30 mg of the antibody at an interval of about every 26 weeks;g) about 30 mg of the antibody at an interval of about every 6 months;h) about 30 mg of the antibody at an interval of about every 28 weeks;i) about 100 mg of the antibody at an interval of about every 24 weeks;j) about 100 mg of the antibody at an interval of about every 26 weeks;k) about 100 mg of the antibody at an interval of about every 6 months;Attorney Docket No: 134524-5009- WOl) about 100 mg of the antibody at an interval of about every 28 weeks; m) about 300 mg of the antibody at an interval of about every 24 weeks;n) about 300 mg of the antibody at an interval of about every 26 weeks;o) about 300 mg of the antibody at an interval of about every 6 months;p) about 300 mg of the antibody at an interval of about every 28 weeks;q) about 600 mg of the antibody at an interval of about every 24 weeks;r) about 600 mg of the antibody at an interval of about every 26 weeks;s) about 600 mg of the antibody at an interval of about every 6 months;t) about 600 mg of the antibody at an interval of about every 28 weeks;u) about 1200 mg of the antibody at an interval of about every 24 weeks; v) about 1200 mg of the antibody at an interval of about every 26 weeks; w) about 1200 mg of the antibody at an interval of about every 6 months; or x) about 1200 mg of the antibody at an interval of about every 28 weeks.

48. The method of claim 46 or claim 47, wherein the therapeutically effective dose is administered subcutaneously.

49. The method of any of claims 46-48, wherein the therapeutically effective dose is administered subcutaneously as a single dose.

50. The method of any of claims 46-49, wherein the therapeutically effective dose is administered as two separate doses.

51. The method of claim 49, wherein the two separate doses comprise a first dose administered at day 1 and second dose administered at day 15.

52. The method of claim 50, wherein the first dose and the second dose comprise the same amount of the antibody.

Images